Adult Asthma Care
Guidelines for Nurses: Promoting Control of Asthma

March 2004

Nursing Best Practice Guideline
Shaping the future of Nursing
Greetings from Doris Grinspun  
Executive Director  
Registered Nurses Association of Ontario  

It is with great excitement that the Registered Nurses Association of Ontario (RNAO) disseminates this nursing best practice guideline to you. Evidence-based practice supports the excellence in service that nurses are committed to deliver in our day-to-day practice.

We offer our endless thanks to the many institutions and individuals that are making RNAO’s vision for Nursing Best Practice Guidelines (NBPGs) a reality. The Ontario Ministry of Health and Long-Term Care recognized RNAO’s ability to lead this project and is providing multi-year funding. Tazim Virani–NBPG project director–with her fearless determination and skills, is moving the project forward faster and stronger than ever imagined. The nursing community, with its commitment and passion for excellence in nursing care, is providing the knowledge and countless hours essential to the creation and evaluation of each guideline. Employers have responded enthusiastically to the request for proposals (RFP), and are opening their organizations to pilot test the NBPGs.

Now comes the true test in this phenomenal journey: will nurses utilize the guidelines in their day-to-day practice? Successful uptake of these NBPGs requires a concerted effort of four groups: nurses themselves, other healthcare colleagues, nurse educators in academic and practice settings, and employers. After lodging these guidelines into their minds and hearts, knowledgeable and skillful nurses and nursing students need healthy and supportive work environments to help bring these guidelines to life.

We ask that you share this NBPG, and others, with members of the interdisciplinary team. There is much to learn from one another. Together, we can ensure that Ontarians receive the best possible care every time they come in contact with us. Let’s make them the real winners of this important effort!

RNAO will continue to work hard at developing and evaluating future guidelines. We wish you the best for a successful implementation!

Doris Grinspun, RN, MScN, PhD (candidate)

Executive Director  
Registered Nurses Association of Ontario
How to Use this Document

This nursing best practice guideline is a comprehensive document that provides resources necessary to support evidence-based nursing practice related to the control of asthma in adults. Specifically, this guideline focuses on assisting nurses working in diverse practice settings in providing basic asthma care for adults and contains recommendations for Registered Nurses and Registered Practical Nurses on best nursing practices in the key interventions of assessment, education and referral.

While best practice guidelines represent a statement of best practice based on the best available evidence, they are not intended to be applied in a 'cookbook fashion' and replace the nurse's judgment for the individual client. This document needs to be reviewed and applied, based on the specific needs of the organization or practice setting/environment, as well as the needs and wishes of the client.

Nurses, other healthcare professionals and administrators, who are leading and facilitating practice changes, will find this document valuable for the development of such things as policies, procedures, protocols, educational programs, assessment and documentation tools. It is highly recommended that practice settings adapt these guidelines in formats that would meet local needs. This guideline provides some suggested formats for such local adaptation and tailoring.

Organizations wishing to use this guideline may decide to do so in a number of ways:
- Assess current nursing and healthcare practices using the recommendations in the guideline.
- Identify recommendations that will address identified needs or gaps in services.
- Systematically develop a plan to implement the recommendations using associated tools and resources.

RNAO is interested in hearing how you have implemented this guideline. Please contact us to share your story. Implementation resources will be made available through the RNAO website at www.rnao.org/bestpractices to assist individuals and organizations to implement best practice guidelines.
Guideline Development Panel Members

Lisa Cicutto, RN, PhD, ACNP, CAE
Team Leader
Assistant Professor
Faculty of Nursing, University of Toronto
ACNP – Respiratory
The Asthma and Airway Centre –
University Health Network
Toronto, Ontario

Pat Hill Bailey, RN, BN, MHSc, PhD
Professor
School of Nursing
Laurentian University
Sudbury, Ontario

Ann Bartlett, RN, BScN, CAE,
NARTC/Diploma in COPD
Nurse Clinician
Firestone Institute for Respiratory Health
St Joseph’s Healthcare
Hamilton, Ontario

Janice Bissonnette, RN, MScN, CAE, CNCC(C)
Clinical Nurse Specialist
Queensway – Carleton Hospital
Ottawa, Ontario

Naomi Cornelius, RPN*
Manager, Resident Care/Service
Needs Coordinator
Churchill Place Retirement Home
Oakville, Ontario

Julie Duff Cloutier, RN, BScN, MSc, CAE
Assistant Professor
School of Nursing
Laurentian University
Sudbury, Ontario

Khiroon Kay Khan, RN, CAE,
NARTC/Diploma in Asthma and COPD
Clinical Nurse Educator
The Asthma and Airway Centre
University Health Network –
Toronto Western Hospital
Toronto, Ontario

Donna Lockett, PhD
Research Associate
University of Ottawa
Community Health Research Unit
Ottawa, Ontario

Heather McConnell, RN, BScN, MA(Ed)
RNAO Project Staff – Facilitator
Project Manager, Nursing Best Practice
Guidelines Project
Registered Nurses Association of Ontario
Toronto, Ontario

* Contributed to the initial development of the guideline.
Jennifer Olajos-Clow, RN, BA/BPHE, BNSc, MSc, CAE
Asthma Educator
Asthma Education Centre
Kingston General Hospital
Kingston, Ontario

Ruth Pollock, RN, MScN
Professional Practice Leader – Nursing
Cornwall General Hospital
Cornwall, Ontario

Dale Stedman, RN
Respiratory Coordinator/Consultant
Saint Elizabeth Health Care
Toronto, Ontario

Nursing Best Practice Guideline
Acknowledgement

Stakeholders representing diverse perspectives were solicited for their feedback and the Registered Nurses Association of Ontario wishes to acknowledge the following for their contribution in reviewing this Nursing Best Practice Guideline.*

Dr. Wally Bartfay  
Queen's University  
Kingston, Ontario

Charlene Bennison, BScPhm, CAE, MEd  
Pharmacist  
North Bay, Ontario

Gabrielle Bridle, RPN  
President, Registered Practical Nurses Association of Ontario  
Mississauga, Ontario

Christine Burchat, BPhm  
Pharmacist  
Queensway – Carleton Hospital  
Ottawa, Ontario

Paula Burns, RRCP, BSc, MAEd, CAE  
Consumer Reviewer  
The Michener Institute for Applied Health Sciences  
Toronto, Ontario

Corinne Chapman, RN, BA, MHSc  
Credit Valley Hospital  
Mississauga, Ontario

Tracey Crosbie  
Director, Registered Practical Nurses Association of Ontario  
Mississauga, Ontario

Lenora Duhn, RN, MSc  
Clinical Nurse Specialist  
Kingston General Hospital  
Kingston, Ontario

Dr. Anthony D’Urzo  
Family Physician  
Toronto, Ontario

Donna George, RPN  
Retired  
Aylmer, Ontario

Rosario Holmes, BS, MA, RRT  
Asthma Education Centre  
Ontario Lung Association  
Ottawa, Ontario

Patricia Hussack, RN  
Research Nurse  
St. Joseph’s Health Care  
McMaster University  
Hamilton, Ontario

Dr. Susan Janson, RN, ANP, DNSc, FAAN  
Professor/Alumnae Chair  
Department of Community Health Systems  
Adjunct Professor, Department of Medicine  
University of California  
San Francisco, California
Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma

Dr. Allan Kaplan
Family Physician
Richmond Hill, Ontario

Judith Kleffman
Consumer Reviewer
Kingston, Ontario

Dr. Diane Lougheed
Respirologist
Kingston General Hospital
Kingston, Ontario

Dr. Josiah Lowry
Family Physician
Orillia, Ontario

Dr. Warren McIssac
General Internal Medicine
Mt Sinai Hospital
Toronto, Ontario

Alwyn Moyer, RN, MSc(A), PhD
Adjunct Professor
University of Ottawa
Ottawa, Ontario

Allistair Packman
Pharmacist
Kingston General Hospital
Kingston, Ontario

Kimberly Peterson
Chief Nursing Officer and
Program Officer of Medicine
Cornwall General Hospital
Cornwall, Ontario

Terry Richmond, RN
Kingston General Hospital
Kingston, Ontario

Shelley Rochette, RN
Queensway – Carleton Hospital
Ottawa, Ontario

Cathy Seymour, RN
Kingston General Hospital
Kingston, Ontario

Joanne Williscroft, RN(EC)
Respiratory Care Clinic
Cornwall General Hospital
Cornwall, Ontario

Karen Zalan, BScPT, CAE
Physiotherapist
Sudbury Regional Hospital
Sudbury, Ontario
Queensway – Carleton Hospital
Focus Group
Ottawa, Ontario

Karen Carruthers, RN
Staff Nurse
Medical Project Manager Charting Systems

Nancy Flynn, RN, BScN
Nurse Manager
Medical/Palliative

Linda Hay, RN, BScN
Palliative Care Coordinator

Kristine Kennedy RN, BScN
Staff Nurse ICU/CCU

Lisa Lynch RN
Staff Nurse Surgery

Evelyn Reddy RN,
Team Leader Medicine

Shay Savoy-Bird RN, BScN
Nurse Manager Surgery

* The above acknowledgements reflect the information provided by the stakeholder at the time the feedback was provided.
RNAO wishes to acknowledge the following organization in Mississauga, Ontario for their role in pilot testing this guideline:

- Trillium Health Centre
  Mississauga, Ontario

RNAO sincerely acknowledges the leadership and dedication of the researchers who have directed the evaluation of the Nursing Best Practice Guidelines Project. The Evaluation Team is comprised of:

**Principal Investigators:**
Nancy Edwards, RN, PhD
Barbara Davies, RN, PhD
University of Ottawa

**Evaluation Team:**
Maureen Dobbins, RN, PhD
Jenny Ploeg, RN, PhD
Jennifer Skelly, RN, PhD
McMaster University

Patricia Griffin, RN, PhD
University of Ottawa

**Project Staff:**
University of Ottawa
Barbara Helliwell, BA(Hons); Marilynn Kuhn, MHA; Diana Ehlers, MA(SW), MA(Dem); Christy-Ann Drouin, BBA; Sabrina Farmer, BA; Mandy Fisher, BN, MSc(cand); Lian Kitts, RN; Elana Ptack, BA

**Contact Information**

**Registered Nurses Association of Ontario**
Nursing Best Practice Guidelines Project
111 Richmond Street West, Suite 1100
Toronto, Ontario
M5H 2G4

**Registered Nurses Association of Ontario**
Head Office
438 University Avenue, Suite 1600
Toronto, Ontario
M5G 2K8
Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma

Disclaimer
These best practice guidelines are related only to nursing practice and not intended to take into account fiscal efficiencies. These guidelines are not binding for nurses and their use should be flexible to accommodate client/family wishes and local circumstances. They neither constitute a liability or discharge from liability. While every effort has been made to ensure the accuracy of the contents at the time of publication, neither the authors nor RNAO give any guarantee as to the accuracy of the information contained in them, nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omissions in the contents of this work. Any reference throughout the document to specific pharmaceutical products as examples does not imply endorsement of any of these products.

Copyright
With the exception of those portions of this document for which a specific prohibition or limitation against copying appears, the balance of this document may be produced, reproduced and published in its entirety, in any form, including in electronic form, for educational or non-commercial purposes only, without requiring the consent or permission of the Registered Nurses Association of Ontario, provided that an appropriate credit or citation appears in the copied work as follows:

table of contents

Summary of Recommendations .................................................. 12
Interpretation of Evidence .......................................................... 16
Responsibility for Development ................................................... 17
Purpose and Scope ...................................................................... 17
Guideline Development Process ................................................... 18
Definition of Terms ...................................................................... 22
Background Context ..................................................................... 24
Practice Recommendations .......................................................... 30
Education Recommendations ...................................................... 38
Organization & Policy Recommendations ..................................... 39
Evaluation & Monitoring .............................................................. 41
Implementation Tips ...................................................................... 42
Process for Update/Review of Guideline ......................................... 44
References .................................................................................. 45
Bibliography ............................................................................... 52
Appendix A – Search Strategy for Existing Evidence .............................. 61
Appendix B – Glossary of Terms .......................................................... 66
Appendix C – Assessing Asthma Control ................................................ 69
Appendix D – Asthma Medications ......................................................... 70
Appendix E – Device Technique ............................................................ 78
Appendix F – What is an Asthma Action Plan? ....................................... 84
Appendix G – Sample Asthma Action Plans .......................................... 86
Appendix H – Peak Flow Monitoring Tips ............................................. 93
Appendix I – How to Use a Peak Flow Meter (PFM) ............................... 94
Appendix J – Tips for Improving Adherence ........................................... 95
Appendix K – Resources ..................................................................... 96
Appendix L – Asthma Clinics in Ontario ............................................... 98
Appendix M – Description of the Toolkit .............................................. 99
Appendix N – Implementation Resources ............................................. 100
## Summary of Recommendations

<table>
<thead>
<tr>
<th>RECOMMENDATION</th>
<th>*LEVEL OF EVIDENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assessment of Asthma Control</strong></td>
<td></td>
</tr>
<tr>
<td>1.0 All individuals identified as having asthma, or suspected of having asthma, will have their level of asthma control assessed by the nurse.</td>
<td></td>
</tr>
</tbody>
</table>
| 1.1 Every client should be screened to identify those most likely to be affected by asthma. As part of the basic respiratory assessment, nurses should ask every client two questions:  
- Have you ever been told by a physician that you have asthma?  
- Have you ever used a puffer/inhaler or asthma medication for breathing problems? | Level IV |
| 1.2 For individuals identified as having asthma or suspected of having asthma, the level of asthma control should be assessed by the nurse. Nurses should be knowledgeable about the acceptable parameters of asthma control, which are:  
- use of inhaled short-acting β2 agonist <4 times/week (unless for exercise);  
- experience of daytime asthma symptoms <4 times/week;  
- experience of night time asthma symptoms <1 time/week;  
- normal physical activity levels;  
- no absence from work or school; and  
- infrequent and mild exacerbations. | Level IV |
| 1.3 For individuals identified as potentially having uncontrolled asthma, the level of acuity needs to be assessed by the nurse and an appropriate medical referral provided, i.e., urgent care or follow-up appointment. | Level IV |
| **Asthma Education** | |
| 2.0 Asthma education, provided by the nurse, must be an essential component of care. | |
| 2.1 The client's asthma knowledge and skills should be assessed and where gaps are identified, asthma education should be provided. | Level I |

* See pg. 16 for details regarding “Interpretation of Evidence”.
### RECOMMENDATION | LEVEL OF EVIDENCE
--- | ---
2.2 Education should include as a minimum, the following:
- basic facts about asthma;
- roles/rationale for medications;
- device technique(s);
- self-monitoring; and
- action plans. | Level IV

### Action Plans
3.1 Every client with asthma should have an individualized asthma action plan for guided self-management based on evaluation of symptoms with or without peak flow measurement, developed in partnership with a healthcare professional. | Level I

3.2 For every client with asthma, the nurse needs to assess for use and understanding of the asthma action plan. If a client does not have an action plan, the nurse needs to provide a sample action plan, explain its purpose and use, and coach the client to complete the plan with his/her asthma care provider. | Level V

3.3 Where deemed appropriate, the nurse should assess, assist and educate clients in measuring peak expiratory flow rates. A standardized format should be used for teaching clients how to use peak flow measurements. | Level IV

### Medications
4.0 Nurses will understand and be able to discuss with clients their medications. | Level I

4.1 Nurses will understand and be able to discuss the two main categories of asthma medications (controllers and relievers) with their clients. | Level IV

4.2 All asthma clients should have their inhaler/device technique assessed by the nurse to ensure accurate use. Clients with sub-optimal technique will be coached in proper inhaler/device use. | Level I
### Referrals

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0 The nurse will facilitate referrals as appropriate.</td>
<td>Level II</td>
</tr>
<tr>
<td>5.1 Clients with poorly controlled asthma should be referred to their physician.</td>
<td>Level II</td>
</tr>
<tr>
<td>5.2 All clients should be offered links to community resources.</td>
<td>Level IV</td>
</tr>
<tr>
<td>5.3 Clients should be referred to an asthma educator in their community, if appropriate and available.</td>
<td>Level IV</td>
</tr>
</tbody>
</table>

### Education Recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level of Evidence</th>
</tr>
</thead>
</table>
| 6.0 Nurses working with individuals with asthma must have the appropriate knowledge and skills to:  
  - identify the level of asthma control;  
  - provide basic asthma education; and  
  - conduct appropriate referrals to physician and community resources. | Level IV |

### Organization and Policy Recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.0 Organizations should have available placebos and spacer devices for teaching, sample templates of action plans, educational materials, and resources for client and nurse education and where indicated, peak flow monitoring equipment.</td>
<td>Level IV</td>
</tr>
<tr>
<td>8.0 Organizations must promote a collaborative practice model within an interdisciplinary team to enhance asthma care.</td>
<td>Level IV</td>
</tr>
<tr>
<td>9.0 Organizations need to ensure that a critical mass of health professionals are educated and supported to implement the asthma best practice guidelines in order to ensure sustainability.</td>
<td>Level V</td>
</tr>
<tr>
<td>10.0 Agencies and funders need to allocate appropriate resources to ensure adequate staffing and a positive healthy work environment.</td>
<td>Level V</td>
</tr>
</tbody>
</table>
Nursing best practice guidelines can be successfully implemented only when there are adequate planning, resources, organizational and administrative support, and appropriate facilitation. Organizations may develop a plan for implementation that includes:

- An assessment of organizational readiness and barriers to education.
- Involvement of all members (whether in a direct or indirect supportive function) who will contribute to the implementation process.
- Dedication of a qualified individual to provide the support needed for the education and implementation process.
- Ongoing opportunities for discussion and education to reinforce the importance of best practices.
- Opportunities for reflection on personal and organizational experience in implementing guidelines.

In this regard, RNAO (through a panel of nurses, researchers and administrators) has developed the **Toolkit: Implementation of Clinical Practice Guidelines** based on available evidence, theoretical perspectives and consensus. The Toolkit is recommended for guiding the implementation of Adult Asthma Care Guidelines for Nurses – Promoting Control of Asthma.
## Interpretation of Evidence

The recommendations made in this best practice guideline have been critically reviewed and categorized by level of evidence. The following taxonomy provides the definitions of the levels of evidence and the rating system (Boulet et al., 1999).

<table>
<thead>
<tr>
<th>LEVEL</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEVEL I</strong></td>
<td>Evidence is based on randomized controlled trials (or meta-analysis of such trials) of adequate size to ensure a low risk of incorporating false-positive or false-negative results.</td>
</tr>
<tr>
<td><strong>LEVEL II</strong></td>
<td>Evidence is based on randomized controlled trials that are too small to provide Level I evidence. They may show either positive trends that are not statistically significant or no trends and are associated with a high risk of false-negative results.</td>
</tr>
<tr>
<td><strong>LEVEL III</strong></td>
<td>Evidence is based on non-randomized controlled or cohort studies, case series, case-control studies or cross-sectional studies.</td>
</tr>
<tr>
<td><strong>LEVEL IV</strong></td>
<td>Evidence is based on the opinion of respected authorities or expert committees as indicated in published consensus conferences or guidelines.</td>
</tr>
<tr>
<td><strong>LEVEL V</strong></td>
<td>Evidence is based on the opinions of those who have written and reviewed the guideline, based on their experience, knowledge of the relevant literature and discussion with their peers.</td>
</tr>
</tbody>
</table>
Responsibility for Development

The Registered Nurses Association of Ontario (RNAO), with funding from the Ministry of Health and Long-Term Care, has embarked on a multi-year project of nursing best practice guideline development, pilot implementation, evaluation and dissemination. In this third cycle of the project, one of the areas of emphasis is on the assessment and management of asthma in adults. This guideline was developed by a panel of nurses and researchers convened by the RNAO, conducting its work independent of any bias or influence from the Ministry of Health and Long-Term Care.

Purpose and Scope

The purpose of this best practice guideline is to provide nurses (RNs and RPNs) working in diverse settings with an evidence-based summary of basic asthma care for adults. The guideline aims to assist nurses and their clients to make informed decisions that lead to quality care and improved outcomes (improved quality of life and overall reduction in morbidity). It is not the intent of the best practice guideline to provide a comprehensive review of the literature or duplicate the recommendations of the Canadian Asthma Consensus Report. Rather, this document is designed to complement and expand upon existing guidelines. This best practice guideline assists nurses who are not specialists in asthma care to identify adults with asthma, determine whether or not their asthma is under acceptable control, provide asthma education (specifically, self-management action plans, use of inhaler/devices and medications), facilitate appropriate referral(s), and access community resources. It is acknowledged that successful asthma control involves a partnership with the individual with asthma and the interdisciplinary healthcare team.

Key Points

- This document focuses on assisting nurses working in diverse practice settings in providing basic asthma care.
- Nurses have an important role in promoting control of asthma through assessment, education and referral.
Guideline Development Process

In February of 2001, a panel of nurses and researchers with expertise in asthma care, asthma education and asthma research, from institutional, community and academic settings was convened under the auspices of the RNAO. The panel discussed the purpose of their work, and came to consensus on the scope of the best practice guideline. Subsequently, a search of the literature for clinical practice guidelines, systematic reviews, relevant research articles and websites was conducted. See Appendix A for a detailed outline of the search strategy employed.

Several published international guidelines have systematically reviewed the evidence related to asthma. The adult asthma best practice development panel determined that it was not necessary to repeat a review of all the literature and that existing guidelines would serve as a “foundation” for guideline development.

A total of ten existing clinical practice guidelines for the assessment and management of asthma in adults were identified that met the initial inclusion criteria:

- published in English;
- developed in 1995 or later;
- strictly on the topic of asthma;
- evidence-based (or documentation of evidence); and
- accessible as a complete document.

Members of the development panel critically appraised these ten guidelines using the “Appraisal Instrument for Clinical Guidelines” from Cluzeau et al. (1997). This instrument allows for evaluation in three key dimensions: rigour, content and context, and application. Following the appraisal process, several guidelines were dropped due to low rigour scores (< 20% of criteria met). Guidelines that were identified as being developed in a systematic way, so that their recommendations were reliably and explicitly evidence-based, were selected as “foundation” guidelines. These documents included:
<table>
<thead>
<tr>
<th>Reference</th>
<th>Title</th>
<th>Website/URL</th>
</tr>
</thead>
</table>
The recommendations from the seven foundation guidelines were compared in a summary document using the following subheadings:

1. Criteria of control, optimal ranges, acceptable ranges.
2. Mild, moderate, and severe asthma.
5. Education/Self-management, basic survival skills.
6. Indications for referral and follow-up – asthma centre/specialists.

Following the extraction of identified recommendations and content from the seven guidelines, the panel underwent a process of review, discussion and consensus on the key evidence-based assessment criteria and levels of severity and control, ultimately identifying key subtopic areas for nursing intervention recommendations.

The panel members divided into subgroups to develop draft recommendations for these key nursing interventions. This work included a critical review of the selected literature by the member(s) of the working group, including review of the foundation guidelines, systematic review articles, primary research studies and other supporting literature for the purpose of drafting recommendations. Where evidence was available from randomized controlled trials and systematic reviews, recommendations were based on these data. Where there was a lack of evidence from high quality studies, recommendations were based on the best available evidence or expert opinion. This process yielded an initial set of recommendations, which were reviewed by the entire development panel for potential gaps and need for supporting evidence, leading to consensus on a final draft set of recommendations. Recommendations were only advanced where consensus was achieved.

This draft document was submitted to a set of external stakeholders for review and feedback – a listing and acknowledgement of these reviewers is provided at the front of this document. Stakeholders represented various healthcare professional groups, clients and families, as well as professional associations. External stakeholders were asked to provide feedback using a questionnaire consisting of open and closed-ended questions. The results were compiled and reviewed by the development panel – discussion and consensus resulted in minor revisions to the draft document prior to pilot testing.
A pilot implementation practice setting was identified through a “Request for Proposal” (RFP) process. Practice settings in Ontario were asked to submit a proposal if they were interested in pilot testing the recommendations of the guideline. The proposals underwent an external review process and the successful applicant (practice setting) selected. A nine-month pilot was undertaken to test and evaluate the recommendations for practice in a community-based hospital setting (Mississauga, Ontario).

The development panel reconvened following completion of the pilot to review the experiences of the pilot site, consider the evaluation results and review any new literature published since the initial development phase. All these sources of information were used to update and revise the document prior to publication.

Three new clinical practice guidelines focusing on adult asthma had been published since the initial development phase. To ensure congruency with the development methodology, development panel members appraised these documents using the revised version of the Cluzeau (1997) instrument, the “Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument” (2001). All three guidelines were determined to meet the panel’s criteria for rigour, content and context, and applicability, and were included as resources for the revision phase. These documents included:


### Definition of Terms

For clinical terms not identified here, please refer to the Glossary of Terms, Appendix B.

**Action Plan:** A collaboratively written set of instructions that assists the client to adjust their asthma medication and/or to seek medical attention according to their level of symptoms and/or peak flow rate in order to maintain control.

**Asthma:** A chronic inflammatory disorder of the airways. Airway inflammation contributes to airway hyperresponsiveness, airflow limitation, and recurrent episodes of wheeze, cough, shortness of breath, and chest tightness. These episodes are usually associated with airflow obstruction that is reversible either spontaneously or with treatment. Airway inflammation contributes to airflow obstruction by causing bronchoconstriction, airway edema, mucous plug formation, and airway wall remodeling.

**Asthma Management:** Establishing and maintaining control of a person’s asthma includes education, environmental control measures, appropriate medications, action plans and regular follow-up care.

**Certified Asthma Educator (CAE):** The national certification for asthma educators in Canada, which ensures a common set of technical and teaching competencies. There are two integral aspects of education included in the Certified Asthma Educators certification: current knowledge about asthma, and educational theory and behaviour change process.

**Chronic Obstructive Pulmonary Disease (COPD):** A term that incorporates chronic bronchitis and emphysema, which can occur singularly or in combination. In Canada, this term does not include asthma. Asthma and COPD can co-exist.

**Clinical Practice Guidelines or Best Practice Guidelines:** Systematically developed statements that assist clinicians and patients to make decisions about appropriate management and healthcare use for specific clinical (practice) circumstances.

**Consensus:** A process for making policy decisions, not a scientific method for creating new knowledge. At its best, consensus development merely makes the best use of available information, be that research data or the collective knowledge of participants.
Control of Asthma: Acceptable asthma control is defined by the following parameters: use of inhaled short-acting β₂ agonist <4 times/week (unless for exercise); experience of daytime asthma symptoms <4 times/week; experience of night time asthma symptoms <1 time/week; normal physical activity level; no absence from work or school; and infrequent and mild exacerbations.

Education Recommendations: Statements of educational requirements and educational approaches/strategies for the introduction, implementation, and sustainability of the best practice guideline.

Meta-analysis: Results from several studies, identified in a systematic review, that are combined and summarized quantitatively.

Organization and Policy Recommendations: Statements of conditions required for a practice setting that enable the successful implementation of the best practice guideline. The conditions for success are largely the responsibility of the organization, although they may have implications for policy at a broader government or societal level.

Practice Recommendations: Statements of best practice directed at the practice of healthcare professionals that are ideally evidence-based.
Background Context

Overview
Asthma is one of the most prevalent chronic conditions affecting 2.3 million Canadians over the age of 4 years (Statistics Canada, 2000), with an estimated total cost of between $504 million and $648 million in 1991 (Krahm et al., 1996).

According to the latest statistics, almost 1 million Ontarians aged 4 years and older have been diagnosed with asthma (Statistics Canada, 2000). A significant increase in the prevalence of asthma in Ontario has occurred in recent years – from 7.4% of those aged 4 and older in 1994/95 to 8.9% in 1998/99 (Statistics Canada, 2000).

Although most people with asthma can achieve good asthma control, many do not. Many underestimate the severity and control of their asthma and continue to restrict their everyday activities, and suffer needlessly. Proper asthma management can lead to better asthma control and may reduce the incidence of death from asthma by as much as 80% (Institute for Clinical Evaluative Sciences in Ontario, 1996). These increases in the prevalence of asthma and associated morbidity and cost are occurring despite advances in our understanding and treatment.

What Is Asthma?
Asthma is a chronic inflammatory disorder of the airways characterized by an increase in airway responsiveness and airway narrowing, which leads to difficulty in breathing. Asthma is usually classified as mild, moderate or severe. Although symptoms vary from person to person, common symptoms include shortness of breath, chest tightness, wheezing, and/or coughing.

Asthma episodes may begin suddenly or may have a slow onset with a gradual worsening of symptoms. These episodes can last for a few minutes to several days, and are attributed to a hyperresponsiveness of the airways and are typically reversible (The Lung Association, 2000). The pathology of an asthma episode is depicted in the figures below. The first illustrates the normal airway. When individuals with asthma are exposed to triggers that they are sensitive to, the airway narrows. This narrowing develops in one or two ways:
The airway becomes swollen and plugged with mucous (inflammation), thus making the airway opening considerably smaller. This is depicted in the middle picture. This inflammation can last from a few hours to a few days to a lifetime.

The muscles surrounding the airway tighten and go into spasm (bronchospasm). The picture on the right demonstrates this process.

Regardless of the person’s asthma severity, any loss of asthma control can potentially be life-threatening. The goal of asthma care is to control or prevent the airway inflammation and to minimize the symptoms experienced and interruptions to daily life. Components of asthma management include education, environmental control measures, appropriate medications, action plans, establishing a partnership between the client and provider and regular follow-up care.

**Key points**

- Asthma is a chronic inflammatory disorder of the airways
- Typical symptoms include shortness of breath, chest tightness, wheezing and/or coughing.
- Airflow limitation in asthma is reversible.
- The severity of an asthma episode can range from mild to life-threatening and last from minutes to days.
What causes asthma?

Although the exact cause of asthma is not known, several predisposing factors have been implicated in its development. These include atopy – a greater tendency to have allergic reactions to environmental allergens (Sporik et al., 1990); genetics – a family history of asthma and/or atopy (Larsen, 1992; Millar & Hill, 1998); and exposure to environmental tobacco smoke (Arshad, 1992; Cook & Strachan, 1997; Soyseth, Kongerud & Boe, 1995; Stoddard & Miller, 1995).

There are several triggers that may irritate the hypersensitive airways in people with asthma and provoke an asthma episode. Common triggers include:

a) Irritants such as:

- **Tobacco smoke** (BTS/SIGN, 2003; Boulet et al., 2001, 1999; Chilmonczyk, Salmun & Megathlin, 1993; GINA, 2002; Murray & Morrison, 1986; Murray & Morrison, 1989; NIH, 1997; NZGG, 2002; United States Environmental Protection Agency, 1992);
- **Exercise** (American Academy of Allergies, Asthma, and Immunology et al., 1999; Boulet et al., 1999; GINA, 2002; NZGG, 2002);
- **Exposure to work-related agents or indoor chemicals** (American Academy of Allergy, Asthma, and Immunology et al., 1999; Boulet et al., 1999; Egan, 1985; GINA, 2002; NIH, 1997; NZGG, 2002; Packe, Archer & Ayres, 1983; Salvagio et al., 1970; Usetti et al., 1983; Virchow et al., 1988); and

b) Allergens such as:

- **Pollen** (GINA, 2002; NZGG, 2002; Peat et al., 1993; Suphioglu et al., 1992);
- **Moulds** (GINA, 2002; Hide et al., 1994; NIH, 1997; Zacharasiewicz et al., 1999);
- **Dust mites** (BTS/SIGN, 2003; Boulet et al., 2001; Chapman, Heymann, Wilkins, Brown & Platts-Mills, 1987; GINA, 2002; Kuehr et al., 1995; Marks et al., 1995; NIH, 1997; NZGG, 2002; Platts-Mills, Hayden, Chapman & Wilkins, 1987);
- **Pet dander** (BTS/SIGN, 2003; Boulet et al., 2001; Gelber et al., 1993; GINA, 2002; Kuehr et al., 1995; Millar & Hill, 1998; NIH, 1997; NZGG, 2002; Pollart, 1989; Sears et al., 1993; Sporik et al., 1995; Strachan & Carey, 1995; Warner et al., 1990);
- **Foods or food additives** (Freedman, 1977; GINA, 2002; Lee, 1992; NZGG, 2002; Taylor, Sears & van Herwaarden, 1994); and
- **Cockroach allergen** (Boulet et al., 2001; GINA, 2002; NIH, 1997; Rosenstreich et al., 1997).

+ Despite its potential to be a trigger, with a proper warm up, people with exercise-induced asthma should be able to engage in physical activity (Boulet et al., 1999).
c) Other factors that can trigger or worsen asthma severity:

- **Upper respiratory/viral infections** (Boulet et al., 1999; GINA, 2002; Lemanske, 1989; NIH, 1997; NZGG, 2002; Pattemore, Johnston & Bardin, 1992);
- **Rhinitis/Sinusitis** (Boulet et al., 1999; Corren, Adinoff, Buchmeir & Irvin, 1992; GINA, 2002; Watson, Becker & Simons, 1993);
- **Gastroesophageal reflux** (GINA, 2002; Irwin et al., 1989; NIH, 1997; Nelson, 1984);
- **Sensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDS)** (GINA, 2002; NIH, 1997; NZGG, 2002; Settipane et al., 1995; Szczeklik & Stevenson, 1999; Sampson, 1999); and

Some individuals with asthma may react to only one trigger, others may react to several. Further, an individual’s triggers may change over time. It is important for individuals with asthma to know their triggers and the appropriate steps to reduce exposure (Ministry of Health and Long-Term Care, 2000).

**Key points**

- Common asthma triggers include irritants, allergens, and viral infections.
- Allergic rhinitis, sinusitis or gastroesophageal reflux may aggravate asthma.
- An individual’s triggers may change over time.

**Prevalence and Impact of Asthma**

In Ontario, it is estimated that almost 1 million people (8.9% of the population) over the age of four have asthma (Statistics Canada, 2000). Further, asthma is implicated in at least 155 deaths per year in Ontario (Ministry of Health and Long-Term Care, 2000). An Australian study reported that 45% of people who died from their asthma had been assessed as having mild or moderate asthma (Robertson, Rubinfeld & Bowes, 1990).

Despite medical advances in understanding the disease and the availability of more effective medications, poorly controlled asthma is a significant problem. According to a 2000 national survey (Chapman et al, 2001), more than 6 in 10 individuals with asthma (62%) are poorly controlled – that is, they experienced at least two of the following: daytime symptoms, sleep disturbances, physical activity restrictions, asthma episodes, absenteeism from work or school, and excess use of rescue medication. Similar estimates have been reported for Ontario (Health Canada, 1998).
Our healthcare system is bearing a significant burden in terms of hospitalizations and emergency room visits as a result of poorly controlled asthma. According to the National Population Health Survey 1996-1997 (Statistics Canada, 2000) 18% of people with asthma had visited the emergency department at least once in the past year. In Ontario, 65,109 days spent in hospital were attributed to poorly controlled asthma, costing the healthcare system $44,432,300 (Statistics Canada, 2000). These costs do not factor in other direct costs of the illness, such as physician visits and costs of medications, nor indirect costs, such as disability, absence from school or work, costs related to premature deaths, and traveling expenses to and from hospital. Although total figures for Ontario have not been tabulated, a 1995/1996 study to assess the annual cost of asthma in adult clients in south central Ontario concluded that the unadjusted annual costs were $2,550 per client (Ungar, Coyte, Chapman & MacKeigan, 1998). Multiplying this estimate by approximately 1 million asthmatics in Ontario, it is estimated that over 2.5 billion dollars per year is spent in Ontario on asthma management.

The burden of poorly controlled asthma for the individual is difficult to estimate since a significant number of cases may go unreported and/or undiagnosed. In Ontario, 31% of individuals with asthma reported missing school, work, and/or social functions due to their asthma (ICES, 1996). Even if the individual with asthma is able to attend work or school, ongoing symptoms or medication may alter concentration and performance (National Asthma Control Task Force, 2000).

**Key Points**
- Almost 1 million people in Ontario have been diagnosed with asthma.
- 6 in 10 individuals with asthma are poorly controlled.
- Asthma is implicated in 155 deaths per year in Ontario.
- Most asthma related deaths are preventable.
- Annual costs in Ontario for asthma may be as high as 2.5 billion dollars per year.
Gaining Control Over Asthma

Reducing the burden of asthma requires a greater understanding of why the prevalence of poorly controlled asthma is so high. Despite a high prevalence of uncontrolled asthma, Chapman et al. (2001) noted that most clients (91%) believe that their asthma is adequately controlled, while only 24% of those studied achieved disease control by meeting the six symptom-based criteria listed by the Canadian Asthma Consensus Report (1999). One-half (48%) of patients with poorly controlled asthma who used inhaled steroids did not understand the role of inhaled steroids and one-third (32%) of patients with poorly controlled asthma who used short acting bronchodilators misunderstood the action of quick relief bronchodilators.

The study concluded that people with asthma have:
- low expectations about their asthma control;
- a poor understanding of the role of various medications; and
- learned to live with and tolerate symptoms and limitations that are generally avoidable.

In addition, the survey highlighted that physicians were no better than their clients with asthma regarding the perception of asthma control (Chapman et al., 2001).

Proper care of asthma including education, environmental control measures, appropriate medications, action plans and regular follow-up care leads to optimal asthma control, improved quality of life for individuals with asthma and reduces the burden of healthcare costs. Because nurses are in contact with clients with asthma in a multitude of settings, they are in a unique situation to promote asthma control, identify early indicators of poorly controlled asthma, positively influence self-care practices and facilitate the referral of individuals to community resources and specialized care.

Key Points
- Most individuals with asthma accept poorly controlled asthma as normal or do not recognize that their asthma is out of control.
- Many physicians are not aware when their clients’ asthma is out of control.
- Best Practice Guidelines for nurses are needed to improve understanding and management of asthma.
## Practice Recommendations

### Assessment of Asthma Control

#### Recommendation • 1.0

All individuals identified as having asthma, or suspected of having asthma, will have their level of asthma control determined by the nurse.

#### Recommendation • 1.1

Every client should be screened to identify those most likely to be affected by asthma. As part of the basic respiratory assessment, nurses should ask every client two questions:

- Have you ever been told by a physician that you have asthma?
- Have you ever used a puffer/inhaler or asthma medication for breathing problems? *(Level IV)*

#### Recommendation • 1.2

For individuals identified as having asthma or suspected of having asthma, the level of asthma control should be assessed by the nurse. Nurses should be knowledgeable about the acceptable parameters of asthma control, which are:

- use of inhaled short-acting β₂ agonist < 4 times/week (unless for exercise);
- experience of daytime asthma symptoms < 4 times/week;
- experience of night time asthma symptoms < 1 time/week;
- normal physical activity levels;
- no absence from work or school; and
- infrequent and mild exacerbations. *(Level IV)*
Indicators of Acceptable Asthma Control

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency/Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daytime symptoms</td>
<td>&lt; 4 times/week</td>
</tr>
<tr>
<td>Night-time symptoms</td>
<td>&lt; 1 time/week</td>
</tr>
<tr>
<td>Need for short-acting β₂ agonist</td>
<td>&lt; 4 times/week</td>
</tr>
<tr>
<td>Physical activity</td>
<td>Unaffected</td>
</tr>
<tr>
<td>Exacerbations</td>
<td>Mild, infrequent</td>
</tr>
<tr>
<td>Work/school absence</td>
<td>None</td>
</tr>
<tr>
<td>FEV₁ or PEF rate</td>
<td>&gt; 85% personal best</td>
</tr>
<tr>
<td>PEF diurnal variation</td>
<td>&lt; 15% variation</td>
</tr>
</tbody>
</table>

Adapted from Canadian Asthma Consensus Report (1999, 2001)

If any one parameter exceeds the described frequency/value, then the client may have uncontrolled asthma.

Recommendation • 1.3

For individuals identified as potentially having uncontrolled asthma, the level of acuity needs to be assessed by the nurse and an appropriate medical referral provided, i.e., urgent care or follow-up appointment. *(Level IV)*

Indicators for Immediate Medical Attention

The following criteria should be assessed and supplemented by spirometry, if available (BTS/SIGN, 2003; NZGG, 2002; SIGN, 1999):

- respiration rate greater than 25 breaths/min *(Level III)*;
- pulse greater than 110 beats/min *(Level III)*;
- accessory muscle use *(Level III)*;
- unable to complete a sentence between breaths *(Level III)*;
- person is distressed (fatigue, exhaustion) and agitated (if person says they are in trouble or anxious, or have an impending sense of doom) *(Level III)*;
- confusion *(Level III)*; and
- altered level of consciousness *(Level III)*.

If the client exhibits any one of the above symptoms, then they should be referred for immediate medical attention.
Discussion of Evidence
Several sources confirm an epidemic of poorly controlled asthma (Chapman et al., 2001; Health Canada, 1998; Statistics Canada, 2000). It is essential that individuals at risk of having poorly controlled asthma be identified and their asthma control assessed (Boulet et al., 1999). If any one of the indicators for immediate medical attention is present, clients may be at increased risk of dying (BTS/SIGN, 2003; NZGG, 2002; SIGN, 1999). See Appendix C for individual questions to assess level of asthma control, and a flow-chart of the process.

Note: It is important to mention that the initial screening questions recommended in the respiratory assessment to identify individuals with asthma or at risk of having asthma may also identify those with or at risk of having Chronic Obstructive Pulmonary Disease (COPD). The initial assessment questions are not meant to diagnose or differentiate between asthma and COPD. Establishing the diagnosis of COPD and/or asthma requires pulmonary function testing and cannot be based on history alone. Asthma and COPD can present similarly in terms of symptom experience (cough, dyspnea, shortness of breath) and medications used to manage the conditions (bronchodilators and corticosteroids). In addition, individuals can have both asthma and COPD, causing diagnostic confusion for clients and clinicians.

Asthma Education

Recommendation • 2.0
Asthma education, provided by the nurse, must be an essential component of care.

Recommendation • 2.1
The client’s asthma knowledge and skills should be assessed and where gaps are identified, asthma education should be provided. (Level I)

Recommendation • 2.2
Education should include as a minimum, the following:
- basic facts about asthma;
- roles/rationale for medications;
- device technique(s);
- self-monitoring; and
- action plans. (Level IV)
Basic facts about asthma
- normal versus asthmatic airways;
- what happens during an asthma episode;
- signs and symptoms of control; and
- identification and reduction of triggers.

Roles/rationale for medications (see Appendix D and J)
- when to use reliever (short-term relief) versus controller (long-term control); and
- importance of adherence to prescribed medication.

Device technique(s) (see Appendix E, H and I)
- good inhaler technique;
- use of spacer; and
- peak flow technique and monitoring (optional).

Self-monitoring and action plan (see Appendix F and G)
- what it is and how to use it.

Discussion of Evidence
A number of controlled trials and systematic reviews with and without meta-analysis have consistently demonstrated that asthma education programs improve asthma morbidity and quality of life and reduce healthcare utilization. Asthma education can also be cost effective (Allen, Jones, & Oldenburg, 1995; Bailey et al., 1990; Bolton et al., 1991; Clark & Nothwehr, 1997; Clarke et al., 1986; Côté et al., 2001; Devine, 1996; Fireman et al., 1981; Garrett et al., 1994; Gibson et al., 2003; Hindi-Alexander & Cropp, 1984; Ignacio-Garcia & Gonzalez-Santos, 1995; Lewis et al., 1984; Trautner et al., 1993; Windsor et al., 1990).

The effectiveness of the specific components of asthma education programs has not been empirically established. However, recommendations from practice guidelines and the literature indicate that basic education should include: facts about asthma, signs and symptoms of worsening asthma, self-monitoring strategies, action plan use, information regarding medications and use of devices (BTS/SIGN, 2003; Boulet et al., 1999; Cicutto et al., 1999; Flaum, Lum Lung & Tinkleman, 1997; GINA, 2002; Gibson et al., 2003; NZGG, 2002).

Comprehensive education programs that include strategies of self-management, regular medical supervision and written action plans are associated with better asthma outcomes than programs offering information only (Gibson et al., 2003). Asthma education programs need to use a diverse range of educational strategies and methods (Boulet et al., 1999). Wilson et al.
(1993), in a controlled trial evaluating two forms of asthma self-management education for adults, reported that education provided in groups or individual counseling both showed significant benefits but no difference in outcomes. The group sessions tended to be more cost effective.

Patient adherence is an important factor in the effectiveness of treatment regimes for any chronic illness (Baudinette, 2000). Evidence suggests that non-adherence with medication and treatment plans is a serious problem among people with asthma (Rand, 1998). As many as fifty percent of people with asthma don't follow their prescribed treatment – even individuals who have some understanding of appropriate management strategies have difficulty with adherence (Kolbe et al, 1996). Refer to Appendix J for tips related to improving adherence.

**Action Plans**

**Recommendation • 3.1**
Every client with asthma should have an individualized asthma action plan for guided self-management based on evaluation of symptoms with or without peak flow measurement, developed in partnership with a healthcare professional. *(Level I)*

**Recommendation • 3.2**
For every client with asthma, the nurse needs to assess for use and understanding of the asthma action plan. If a client does not have an action plan, the nurse needs to provide a sample action plan, explain its purpose and use, and coach the client to complete the plan with his/her asthma care provider. *(Level V)*

**Recommendation • 3.3**
Where deemed appropriate, the nurse should assess, assist and educate clients in measuring peak expiratory flow rates. A standardized format should be used for teaching clients how to use peak flow measurements. *(Level IV)*
Discussion of Evidence

The Canadian Asthma Consensus Report (Boulet et al., 1999, 2001), along with other national and international guidelines, recommend that every individual with asthma be provided with a written action plan (BTS/SIGN, 2003; Boulet et al., 1999, 2001; GINA, 2002; NIH, 1997; SIGN, 1998; NZGG, 2002). It is the role of the nurse to facilitate the attainment and effective use of an individualized action plan developed in partnership with the physician and the rest of the asthma care team. This recommendation is based on a substantive amount of evidence. A Cochrane review (Gibson et al., 2003) concluded that self-management programs for adults with asthma that involved self-monitoring, either by peak flow or symptoms, combined with a written action plan and regular medical review resulted in reduced health services use, days lost from work, and episodes of nocturnal asthma. It is noteworthy that the programs that included a written action plan consistently demonstrated benefit whereas those that did not include a written action plan did not always demonstrate benefit. Recently, a case control study was published that reported a 70% reduction in the risk of death for individuals who possessed written action plans (Abramson et al., 2001).

Refer to Appendix F for details about action plans, Appendix G for sample action plans, and Appendix H and I for details regarding the use of Peak Flow Meters.

Peak Flow versus Symptom Monitoring

Studies comparing peak flow monitoring with self-monitoring of symptoms have reported little difference in various asthma outcomes (Charlton, Charlton, Broomfield, & Mullee, 1990; Gibson, Coughlan, Abramson, 1998; Turner, Taylor, Bennett, & Fitzgerald, 1998). However, much debate has focused on the desired method for self-monitoring, specifically peak expiratory flow (PEF) monitoring versus symptom monitoring only. Peak flow measurements provide an objective measurement of lung function, but such measurements have limitations. Côté et al. (1998) have demonstrated that individuals with asthma have difficulty sustaining daily performance and recording of peak flow use. There is also a risk of inaccurate readings resulting from poor technique, misinterpretation of results or device failure (Boulet et al., 1999). Further, several research findings indicate that changes in peak flow are less sensitive than deterioration of symptoms during acute episodes of asthma (Chan-Yeung et al., 1996; Gibson et al., 1990; Malo, L'Archeveque, Trudeau, d’Aquino & Cartier, 1993). A role for action plans based on the regular measurement...
of PEF, however, is suggested in clients who have difficulty recognizing the severity of their symptoms (i.e., ‘poor perceivers’), those with very severe asthma, or those recently requiring emergency department use or hospitalization (Boulet et al., 1999). The choice of peak flow or symptom monitoring may be based on asthma severity, the client’s ability to perceive airflow obstruction, the availability of peak flow meters and, most importantly, client preferences (Boulet et al., 1999; NIH, 1997).

**Medications**

**Recommendation • 4.0**
Nurses will understand and be able to discuss with clients their medications.

**Recommendation • 4.1**
Nurses will understand and be able to discuss the two main categories of asthma medications (controllers and relievers) with their clients. *(Level IV)*

Knowledge of medications includes the following:

- trade and generic names;
- indications;
- doses;
- side effects;
- mode of administration; and
- pharmacokinetics.

**Recommendation • 4.2**
All asthma clients should have their inhaler/device technique assessed by the nurse to ensure accurate use. Clients with sub-optimal technique will be coached in proper inhaler/device use. *(Level I)*
Discussion of Evidence

Many barriers exist regarding the use of medications that prevent people with asthma from adequately controlling their disease. These include possible knowledge deficits regarding the relationship between asthma symptoms and the mechanism of action of asthma medications, inadequate device technique, the complexity of the medication regime, and negative feelings toward taking medication daily. In order to address some of these barriers, the nurse and individual with asthma should be knowledgeable regarding the general classifications of medications, their indications, actions, side effects, usual doses, and administration techniques (Boulet et al., 1999).

Medications used to treat asthma can generally be divided into two categories, controllers (preventers) and relievers. They are available in various forms and are delivered through a variety of devices. The inhaled route is the preferred route as it minimizes systemic availability and therefore minimizes side effects (BTS/SIGN, 2003; Boulet et al., 1999; GINA, 2002; NZGG, 2002; NIH, 1997; Newhouse & Dolovich, 1986). Appendix D provides a detailed description of controllers (preventers) and relievers.

Referrals

**Recommendation • 5.0**
The nurse will facilitate referrals as appropriate.

**Recommendation • 5.1**
Clients with poorly controlled asthma should be referred to their physician. *(Level II)*

**Recommendation • 5.2**
All clients should be offered links to community resources. *(Level IV)*

**Recommendation • 5.3**
Clients should be referred to an asthma educator in their community, if appropriate and available. *(Level IV)*
Discussion of Evidence
Clients may need to be referred to a specialist through their physician if their diagnosis is in doubt or their asthma is not under control (BTS/SIGN, 2003; Boulet et al., 1999; GINA, 2002; Green et al., 2000; NIH, 1997; NZGG, 2002; SIGN, 1998). Evidence suggests asthma is better managed when individuals receive care supplemented by specialists or asthma clinics (BTS/SIGN, 2003; Bartter et al., 1996; Cicutto et al., 2000; Jin et al., 2000; NZGG, 2002; Volmer et al., 1997) as clients are more likely to receive objective lung function measurements, anti-inflammatory therapy, asthma education and regular follow-up care.

Education Recommendations

Recommendation • 6.0

Nurses working with individuals with asthma must have the appropriate knowledge and skills to:

- identify the level of asthma control;
- provide basic asthma education; and
- conduct appropriate referrals to physician and community resources. (Level IV)

Specific areas of knowledge and skills include the following:

- assessment of asthma control;
- effective teaching and communication strategies;
- assessment for gaps in knowledge and skills;
- basic components of asthma education;
- asthma medications (see Appendix D);
- inhaler/device technique (see Appendix E);
- purpose for, and the general structure of, an asthma action plan (see Appendix F and G);
- use of peak flow monitoring (see Appendix H and I); and
- available community resources (see Appendix K and L).
Discussion of Evidence

Individuals with asthma need regular supervision and support by healthcare professionals who are knowledgeable about asthma and its management (BTS/SIGN, 2003; Boulet et al., 1999; GINA, 2002; NZGG, 2002). In order to provide the necessary support and education to adults with asthma, nurses who are not specialists in asthma care require basic skills in these identified areas. Education of healthcare providers about asthma best practices should address the knowledge, skill and attitudes necessary to implement the guideline recommendations (NZGG, 2002).

All healthcare professionals working with adults with asthma require basic education, which should include: the content of the clinical practice guidelines; information about asthma; prevention of exacerbations; training in guided self-management; ability to recognize deteriorating asthma; knowledge about medications; training in the proper use of medication inhalers/devices and peak flow meters. This education should emphasize the importance of preventive management. In addition, healthcare professionals need to recognize that patient education involves giving information and assisting with the acquisition of skills, as well as behaviour change on the part of the individual with asthma. This component of successful client education requires strong communication skills on the part of the provider (GINA, 2002).

Organization & Policy Recommendations

Recommendation • 7.0

Organizations should have available placebos and spacer devices for teaching, sample templates of action plans, educational materials, and resources for client and nurse education and where indicated, peak flow monitoring equipment. (Level IV)

Recommendation • 8.0

Organizations must promote a collaborative practice model within an interdisciplinary team to enhance asthma care. (Level IV)
Recommendation • 9.0
Organizations need to ensure that a critical mass of health professionals are educated and supported to implement the asthma best practice guidelines in order to ensure sustainability. (Level V)

Recommendation • 10.0
Agencies and funders need to allocate appropriate resources to ensure adequate staffing and a positive healthy work environment. (Level V)

Recommendation • 11.0
Nursing best practice guidelines can be successfully implemented only when there are adequate planning, resources, organizational and administrative support, and appropriate facilitation. Organizations may develop a plan for implementation that includes:

- An assessment of organizational readiness and barriers to education.
- Involvement of all members (whether in a direct or indirect supportive function) who will contribute to the implementation process.
- Dedication of a qualified individual to provide the support needed for the education and implementation process.
- Ongoing opportunities for discussion and education to reinforce the importance of best practices.
- Opportunities for reflection on personal and organizational experience in implementing guidelines.

In this regard, RNAO (through a panel of nurses, researchers and administrators) has developed the *Toolkit: Implementation of Clinical Practice Guidelines* based on available evidence, theoretical perspectives and consensus. The *Toolkit* is recommended for guiding the implementation of *Adult Asthma Care Guidelines for Nurses – Promoting Control of Asthma*. (Level IV)

Refer to Appendix M for a description of the Toolkit.
### Evaluation & Monitoring

Organizations implementing the recommendations in this nursing best practice guideline are advised to consider how the implementation and its impact will be monitored and evaluated. The following table, based on the framework outlined in the *Toolkit: Implementation of Clinical Practice Guidelines (2002)*, summarizes some suggested indicators for monitoring and evaluation:

<table>
<thead>
<tr>
<th>Level of Indicator</th>
<th>Structure</th>
<th>Process</th>
<th>Outcome</th>
</tr>
</thead>
</table>
| **Organization**   | • Availability of client education resources (sample action plans, referral information) that are consistent with best practice guideline recommendations.  
• Access to placebos (e.g., MDIs, Turbuhaler®, Diskus®), holding chambers (spacers) and peak flow meters for client education.  
• Review of best practice guideline recommendations by organizational committee(s) responsible for policies or procedures;  
• Availability of, and access to, asthma specialists. | • To evaluate changes in practice that lead towards improved control of asthma. | • To evaluate the impact of implementing the recommendations.  
• Policies and procedures related to assessing asthma control are consistent with the guidelines. |
| **Nurse**          | • Availability of educational opportunities related to promoting asthma control within the organization.  
• Number of nurses attending educational sessions related to promoting asthma control. | • Level of asthma control assessed, including:  
• inhaled short acting & use;  
• night time awakenings;  
• daytime symptoms;  
• interruption with daily activities.  
• Nurses’ self-assessed knowledge of:  
• asthma control criteria;  
• two main categories of asthma medication;  
• correct inhaler/device technique;  
• asthma action plans; and  
• available educational materials and community resources. | • Evidence of documentation in client record consistent with guideline recommendations regarding:  
• assessment of asthma control;  
• assessment of inhaler/device technique;  
• provision of asthma education;  
• review of action plan;  
• referral to asthma educator, asthma clinic or other community resource. |
Examples of evaluation tools that were used to collect data on some of the indicators identified above during the pilot implementation/evaluation of this guideline are available at www.rnao.org/bestpractices.

**Implementation Tips**

This best practice guideline was pilot tested at Trillium Health Centre, a large two site acute care community-based hospital serving south Mississauga and Etobicoke, Ontario. The lessons learned and results of the pilot implementation may not be appropriate to generalize to other settings. However, there were many strategies used that the pilot site found helpful during implementation. Those who are interested in implementing this guideline may wish to consider these tips. A summary of these strategies follows:

- Communicating and raising awareness of asthma and the best practice guideline is critical. Consider having a project launch, use your agency’s newsletter, or create a project news bulletin.
- Remember to set small incremental goals and to celebrate achieving your milestones.
- Consider “branding” your project with a logo or other form of identification – this logo can be used on all memos, posters and printed material to help identify and heighten project awareness around the organization.
Transfer strategies that were helpful in nursing education included:

- The development of clinical area specific education sessions. For example, content was tailored specifically for the nurses of the emergency department, inpatient units and outpatient clinics.
- The development of a patient pathway (see Appendix N) and two different documentation tools for the emergency and in-patient departments allowed the nurses to target their assessment and teaching to the client’s needs. This reduced duplication of nursing workload.
- Pre-learning packages allowed nurses to familiarize themselves with some of the content prior to attending the educational sessions. This reduced the amount of content to be covered in the class, and allowed for more active involvement by participants in the session. The packages also acted as a source for a “refresher” after the sessions were complete.
- A train-the-trainer approach proved to be helpful. After nurses received their education, they wore the project logo (a stoplight) on their name tag to identify themselves as someone that had completed their education and could act as a resource person to assist with patient teaching.
- Once the initial education session was complete, the nurses facilitating the project implementation booked time on the nursing units to conduct short 15 minute review “in-services”. These refresher sessions used games and activities to help the nurses review their skills with medication devices, drug categories, and the use of a patient teaching booklet.
- Patient teaching resources were placed in each of the clinical areas. These resources contained teaching tools such as medication placebos, patient education booklets and other materials that a nurse would need to teach clients and families.

In addition to the tips mentioned above, RNAO has published implementation resources that are available on the website. A Toolkit for implementing guidelines can be helpful, if used appropriately. A brief description about this Toolkit can be found in Appendix M. It is available for free download at www.rnao.org/bestpractices. Implementation resources developed by the pilot site are also available on the website to assist individuals and organizations implement this best practice guideline. These resources are specific to the pilot site, and have been made available as examples of local adaptation for guideline implementation.
# Process For Update/Review of Guideline

The Registered Nurses Association of Ontario proposes to update the Best Practice Guidelines as follows:

1. Following dissemination, each nursing best practice guideline will be reviewed by a team of specialists (Review Team) in the topic area every three years following the last set of revisions.

2. During the three-year period between development and revision, RNAO Nursing Best Practice Guideline project staff will regularly monitor for new systematic reviews, meta-analysis papers and randomized controlled trials (RCTs) in the field.

3. Based on the results of the monitor, project staff may recommend an earlier revision period. Appropriate consultation with a team comprised of original panel members and other specialists in the field will help inform the decision to review and revise the best practice guideline earlier than the three year milestone.

4. Three months prior to the three year review milestone, the project staff will commence planning of the review process as follows:
   a) Invite specialists in the field to participate in the Review Team activities. The Review Team will be comprised of members from the original panel as well as other recommended specialists.
   b) Compilation of feedback received, and questions encountered during the dissemination phase as well as other comments and experiences of implementation sites.
   c) Compilation of new clinical practice guidelines in the field, systematic reviews, meta-analysis papers, technical reviews and randomized controlled trial research.
   d) Develop a detailed work plan with target dates for deliverables.

The revised guideline will undergo dissemination based on established structures and processes.
References


Marks, G., Tovey, E., Green, W., Shearer, M., Salome, C., & Woolcock, A. (1995). The effect of changes in house dust mite allergen exposure on the severity of asthma. *Clinical Experimental Allergy, 25*(2), 114-118.


Peat, J., Tovey, E., Mellis, C. M., Leeder, S. R., & Woolcock, A. J. (1993). Importance of house dust mite and Alternaria allergens in childhood asthma: An epidemiological study in two climatic regions of Australia. *Clinical and Experimental Allergy, 23*(10), 812-820.


Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma


Warner, J. & et al (1990). The influence of exposure to house dust mite, cat pollen and fungal allergens in the home on primary sensitization in asthma. Pediatric Allergy Immunology, 1, 79-86.


Bibliography


Cicuttio, L. (2002a). Review: Pressurised metered dose inhalers are as effective as other hand held inhalers for delivering β2 agonist bronchodilators in stable asthma. *Evidence Based Nursing, 5*(2), 45.
Cicuttto, L. (2002b). Review: Pressurised metered dose inhalers are as effective as other hand held inhalers for delivering corticosteroids in stable asthma. *Evidence Based Nursing, 5*(2), 44.


Marabini, A., Brugnami, G., Curradi, F., Casciola, G., Stopponi, R., Pettinari, L. et al. (2002). Short-term effectiveness of an asthma educational program: Results of a randomized controlled trial. Respiratory Medicine, 96(12), 993-998.


Appendix A: Search Strategy for Existing Evidence

STEP 1 – Database Search
An initial database search for existing asthma guidelines was conducted in early 2001 by a company that specializes in searches of the literature for health related organizations, researchers and consultants. A subsequent search of the MEDLINE, Embase, and CINAHL databases for articles published from January 1, 1995 to February 28, 2001 was conducted using the following search terms and key words: “asthma”, “self care”, “self management”, “practice guideline(s)”, “clinical practice guideline(s)”, “standards”, “consensus statement(s)”, “consensus”, “evidence-based guidelines”, and “best practice guidelines”. In addition, a search of the Cochrane Library database for systematic reviews was conducted concurrently using the above search terms.

STEP 2 – Internet Search
A metacrawler search engine (metacrawler.com) plus other available information provided by the project team was used to create a list of websites known for publishing or storing clinical practice guidelines. The following sites were searched in early 2001:

- Agency for Healthcare Research and Quality: www.ahrq.gov
- American Medical Association: www.ama-assn.org/
- Best Practice Network: www.best4health.org
- Canadian Centre for Health Evidence: www.ccne.net
- Canadian Institute for Health Information (CIHI): www.cihi.ca/index.html
- Canadian Medical Association Guideline Infobase: www.cma.ca/eng-index.htm
- Canadian Task Force on Preventative Health Care: www.ctfphc.org/
- Cancer Care Ontario: www.cancercare.on.ca
- Centre for Disease Control: www.cdc.gov
- Centre for Evidence-Based Child Health: www.ich.bpmf.ac.uk/ebm/ebm.htm
Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma

- Centre for Evidence-Based Medicine: [www.cebm.jr2.ox.ac.uk/](http://www.cebm.jr2.ox.ac.uk/)
- Centre for Evidence-Based Mental Health: [www.psychiatry.ox.ac.uk/cebmh/](http://www.psychiatry.ox.ac.uk/cebmh/)
- Centre for Evidence-Based Nursing: [www.york.ac.uk/depts/hstd/centres/evidence/ev-intro.htm](http://www.york.ac.uk/depts/hstd/centres/evidence/ev-intro.htm)
- Centre for Health Services Research: [www.nci.ac.uk/chsr/publicn/tools/](http://www.nci.ac.uk/chsr/publicn/tools/)
- Core Library for Evidence-Based Practice: [www.shef.ac.uk/~scharr/ir/core.html](http://www.shef.ac.uk/~scharr/ir/core.html)
- Clinical Resource Efficiency Support Team (CREST): [www.n-i.nhs.uk/crest/index.htm](http://www.n-i.nhs.uk/crest/index.htm)
- Evidence-based Nursing: [www.bmj.com/data/ebn.htm](http://www.bmj.com/data/ebn.htm)
- Health Canada: [www.hc-sc.gc.ca](http://www.hc-sc.gc.ca)
- Institute for Clinical Evaluative Sciences (ICES): [www.ices.on.ca/](http://www.ices.on.ca/)
- Institute for Clinical System Improvement (ICSI): [www.icsi.org](http://www.icsi.org)
- Journal of Evidence-Based Medicine: [www.bmj.com/data/ebm.htm](http://www.bmj.com/data/ebm.htm)
- McMaster University Evidence-Based Medicine site: [www.hiru.hirunet.mcmaster.ca/ebm](http://www.hiru.hirunet.mcmaster.ca/ebm)
- McMaster Evidence-Based Practice Centre: [www.hiru.mcmaster.ca/epc/](http://www.hiru.mcmaster.ca/epc/)
- Netting the Evidence: A SchHARR Introduction to Evidence-Based practice on the Internet: [www.shef.ac.uk/uni/academic/](http://www.shef.ac.uk/uni/academic/)
- Primary Care Clinical Practice Guidelines: [www.medicine.ucsf.edu/resources/guidelines/](http://www.medicine.ucsf.edu/resources/guidelines/)
- Royal College of Nursing: [www.rcn.org.uk](http://www.rcn.org.uk)
- Scottish Intercollegiate Guidelines Network: [www.show.scot.nhs.uk/sign/home.htm](http://www.show.scot.nhs.uk/sign/home.htm)
- TRIP Database: [www.tripdatabase.com/publications.cfm](http://www.tripdatabase.com/publications.cfm)
- Turning Research into Practice: [www.gwent.nhs.gov/uk/trip/](http://www.gwent.nhs.gov/uk/trip/)
- University of California: [www.library.ucla.edu/libraries/biomed/cdd/clinprac.htm](http://www.library.ucla.edu/libraries/biomed/cdd/clinprac.htm)
One individual searched each of these sites. The presence or absence of guidelines was noted for each site searched – at times it was indicated that the website did not house a guideline but re-directed to another website or source for guideline retrieval. A full version of the document was retrieved for all guidelines.

STEP 3 – Hand Search/Panel Contributions

Panel members were asked to review personal archives to identify guidelines not previously identified. In a rare instance, a guideline was identified by panel members and not found through the database or Internet search. These guidelines were developed by local groups and had not been published to date. Results of this strategy revealed no additional clinical practice guidelines.

STEP 4 – Core Screening Criteria

This search method revealed multiple guidelines, several systematic reviews and numerous articles related to asthma. The final step in determining whether the clinical practice guideline would be critically appraised was to apply the following criteria:

- guideline was in English;
- guideline was dated 1995 or later;
- guideline was strictly about the topic area;
- guideline was evidence-based, i.e., contained references, description of evidence, sources of evidence; and
- guideline was available and accessible for retrieval.

Ten guidelines identified were deemed suitable for critical review using the Cluzeau et al. (1997) Appraisal Instrument for Clinical Practice Guidelines.
<table>
<thead>
<tr>
<th>Title of the Practice Guideline Retrieved and Critically Appraised</th>
</tr>
</thead>
</table>
Three additional guidelines were identified and critically appraised during the guideline revision. These were appraised using the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument (The AGREE Collaboration, 2001).


Nursing Best Practice Guideline
### Appendix B: Glossary of Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agonist</strong></td>
<td>A substance that mimics, stimulates or enhances the normal physiological response of the body.</td>
</tr>
<tr>
<td><strong>Airway Remodeling</strong></td>
<td>A collective term that encompasses the alterations in structural cells and tissues in the airways of some individuals with asthma, which may or may not be reversible.</td>
</tr>
<tr>
<td><strong>Allergen</strong></td>
<td>A protein or non-protein substance that is capable of inducing an allergic reaction or hypersensitivity. Common allergens can include: house dust mites, house dust, animals, food, mould, and pollen.</td>
</tr>
<tr>
<td><strong>Antagonist</strong></td>
<td>A substance that inhibits the normal physiological response of the body.</td>
</tr>
<tr>
<td><strong>Asthma Episode</strong></td>
<td>A worsening of asthma symptoms caused by bronchoconstriction, also referred to as an asthma attack, asthma exacerbation or asthma flare-up, in which the individual's asthma is out of control.</td>
</tr>
<tr>
<td><strong>Atopy</strong></td>
<td>Development of an immunoglobulin E (IgE) mediated response to common allergens.</td>
</tr>
<tr>
<td><strong>β₂ Agonist</strong></td>
<td>A group of bronchodilators resulting in smooth muscle relaxation and bronchodilation through stimulation of β₂ receptors found on airway smooth muscle.</td>
</tr>
<tr>
<td><strong>Bronchoconstriction</strong></td>
<td>A narrowing of the airway caused by bronchial smooth muscle contraction (tightening) and airway inflammation (swelling).</td>
</tr>
<tr>
<td><strong>Bronchodilators</strong></td>
<td>A category of medications that produce relaxation of the smooth muscles surrounding the bronchi, resulting in dilatation of the airways. See Relievers</td>
</tr>
<tr>
<td><strong>Controllers</strong></td>
<td>Controllers are medications that are taken regularly on a daily basis to minimize asthma symptoms from occurring and prevent exacerbations. They may also be known as preventers.</td>
</tr>
</tbody>
</table>
Corticosteroids: A group of synthetic hormones that suppress the various inflammatory processes involved with asthma and are currently the most effective maintenance therapy for most patients. See Controllers

Dry-Powder Inhaler (DPI): A breath activated device used to deliver medication in powder form to the lungs.

Forced Expiratory Volume in the first second in liters (FEV₁): The measure of the maximum volume of air a person can breathe out from the lungs in the first second of a forced expiratory manoeuvre. It is the most important measurement for monitoring obstructive lung disease and determines the severity of airway obstruction. The normal value is > 80% of the predicted value. See Spirometry

Hyperresponsiveness: The tendency of the smooth muscle of the airway to contract more intensely in response to a given stimulus/irritant than it does in a normal airway. This condition is present in virtually all symptomatic individuals with asthma. The most prominent manifestation of this smooth muscle contraction is airway narrowing.

Irritants: A class of triggers that are non-allergic that can provoke asthma symptoms.

Leukotriene-Receptor Antagonists (LTRA): A non-steroidal anti-inflammatory medication that works by blocking the leukotriene receptors on cells involved in the inflammatory process.

Metered Dose Inhaler (MDI): A hand activated device used for delivering an aerosolized medication to the lungs.

Metered Dose Inhaler, Chlorofluorocarbon Propelled – MDI(CFC): A metered-dose inhaler using a chlorofluorocarbon as the propellant for aerosolization of medication.

Metered Dose Inhaler, Hydrofluoroalkane Propelled – MDI(HFA): A metered-dose inhaler using a hydrofluoroalkane as the propellant for aerosolization of medication.
**Nebulizer:** A machine that vapourizes medication, using either oxygen or compressed air. The resulting fine mist is inhaled from either a mask over the nose or a mouthpiece.

**Peak Expiratory Flow in L/min (PEF):** A measure of the maximum speed at which a person can forcefully expel air from the lungs following maximal inspiration. It provides a simple, quantitative and reproducible measure of the existence of airflow obstruction. The measurement is effort dependent.

**Peak Flow Meter (PFM):** A portable hand-held device used to measure peak expiratory flow rate.

**Preventers:** see Controllers

**Relievers:** Relievers are medications that are used to relieve asthma symptoms and to prevent asthma symptoms prior to exercise, exposure to cold air or other triggers. See Bronchodilators; β2 agonists.

**Spacers:** A holding chamber device for aerosolized medication that attaches to metered-dose inhalers to make it easier to use, and to deliver more medication to the lungs. They are available in various sizes, with and without masks.

**Spirometry:** A test that measures forced expiratory volumes and flow rates. See FEV₁

**Triggers:** Factors that can provoke asthma symptoms. Every individual with asthma has a unique set of triggers for asthma symptoms. Triggers include both allergens and irritants.
Appendix C: Assessing Asthma Control

Respiratory Screen to Identify those with Asthma

“Have you ever been told by a physician that you have asthma?” OR
“Have you ever used a puffer/inhaler for breathing problems?”

- **YES**
  - Risk of asthma
  - Assess asthma control
    - Do you cough, wheeze, or have chest tightness 3 or more times per week?
    - Do you wake up at night or in the morning with coughing, wheezing or chest tightness one or more times per week?
    - Do you use your blue inhaler (reliever medicine) 3 or more times per week to relieve symptoms (chest tightness, wheeze, cough, dyspnea)? (excluding use for strenuous exercise)
    - Have you changed and/or limited your physical activity because of symptoms (cough, wheeze, chest tightness, SOB) or fear of experiencing symptoms?
  - If **YES** to one or more, Asthma is **UNCONTROLLED**
    - Urgent medical consultation warranted if ANY of the following exist:
      - Respiration rate >25 breaths/min
      - Client is unable to complete a sentence between breaths
      - Client experiences incomplete relief from, or is unresponsive to, short acting inhaled β2 agonist
      - Client is distressed (fatigue, exhaustion) and agitated (individual says they are in trouble or anxious or has an impending sense of doom)
      - Client is confused
      - Client displays an altered level of consciousness
  - **YES** to any of the above, uncontrolled and Urgent Care required
    - Immediate Medical Assistance Required
    - Once stabilized, Provide Education

- **NO**
  - No further asthma assessment
  - **NO** to all of the above, uncontrolled and Non-urgent Care required.
    - Refer to Physician
    - Provide Education
    - Content of Educational Program
      - Basic asthma facts
      - Role/rationale for medications (relievers/controllers)
      - Device technique
      - Self-monitoring asthma control
      - Action plan
Appendix D: Asthma Medications

The Canadian Asthma Consensus Report (1999) stresses the importance of using medications at the minimum dose and frequency required to maintain control of asthma symptoms (Level III). Once control has been established and maintained, physicians should consider reducing the daily dose of inhaled corticosteroids to the lowest dose necessary to control symptoms (Level IV). It is important however to recognize that medications are not to be used as a substitute for proper control of environmental factors, as persistent exposure to inflammatory triggers will require higher doses of medication to control asthma symptoms (Level III).

People with asthma frequently search for complementary therapies to treat their asthma. Whether these treatments are used solely or as adjuvant, there is insufficient evidence demonstrating clinical benefit from complementary therapies (homeopathy, chiropractic, acupuncture, hypnosis and relaxation techniques, herbal medicine as well as Chinese, Japanese and Indian medicines) (Level I or II, depending on the therapy).

Medications used to treat asthma can generally be divided into two categories: relievers and controllers. They are available in various forms and are delivered through a variety of devices, however, the inhaled route is the preferred route as it minimizes systemic availability and therefore minimizes side effects (Level I).

a) Relievers

- Relievers are medications that are used primarily on an as-needed basis to relieve asthma symptoms. They may also be used to prevent asthma symptoms prior to exercise or other triggers.
- They are best represented by short-acting ß2-agonists i.e., salbutamol and terbutaline. Recently, the long-acting ß2-agonist Oxeze (formoterol) was approved for relief of acute bronchoconstriction.
- Relievers are to be used at the lowest dose and frequency required to relieve symptoms.
- Daily use of a short acting reliever for symptom control indicates that a controller (anti-inflammatory) medication is required (Level I). This does not include one dose per day to prevent exercise-induced bronchospasm.
Ipratropium bromide is less effective than short-acting β2-agonists and is not recommended as first line therapy. It may be used as a reliever when short-acting β2-agonists are not well tolerated due to side effects (Level III).

Use of an MDI with spacer is preferred over the use of a nebulizer for all clients of all ages at all levels of severity (Level I).

For emergency situations, β2-agonists should be administered by inhalations and titrated using objective and clinical measures of airflow obstruction as dosage guides (Level I).

In cases of acute asthma, the recommended dosage for β2-agonists is: 4 to 8 puffs every 15-20 minutes. However, it may be necessary to increase the dose to 1 puff every 30-60 seconds (Level IV).

Once maximum relief is achieved, continued administration of bronchodilators by any route is not likely to provide further clinical benefit and may result in toxic effects (Level IV).

b) Controllers (preventers)

Controllers are medications that are taken regularly on a daily basis to minimize asthma symptoms from occurring and to prevent exacerbations.

Controllers are best represented by corticosteroids (inhaled and oral), a potent anti-inflammatory agent, and are considered the most effective medication in this category (Level I).

Corticosteroids

Early initiation of treatment with inhaled corticosteroids, in the natural history of the disease, is associated with a better functional outcome (Level III).

Initial daily dose in adults is commonly in the range of 400-1000µg of beclomethasone or equivalent. Higher doses of inhaled or the addition of oral or systemic corticosteroids may be required if the asthma is more severe (Level III).

When asthma is out of control, it should be treated as soon as possible to prevent a severe exacerbation (Level III). This can be done with a 2 to 4-fold increase in inhaled corticosteroids (Level IV), or prednisone 0.5 to 1.0 mg/kg a day (Level I) as directed by a physician.
Other anti-inflammatories

Other anti-inflammatory medications in the controller category that are non-steroidal include: leukotriene-receptor antagonists and anti-allergic agents (sodium cromoglycate and nedocromil).

Non anti-inflammatories

Other medications are also included in the controller category. These include long-acting β₂-agonists (salmeterol and formoterol), leukotriene-receptor antagonists theophylline, and ipratropium bromide. When additional therapy is required to control asthma symptoms, long-acting β₂-agonists are the primary choice (Level I).

Long-acting β₂-agonists assist corticosteroids in achieving and maintaining asthma control (Level II). Because they mask the underlying airway inflammation, long-acting β₂-agonists must be used in conjunction with inhaled corticosteroids (Level II).

Leukotriene-receptor antagonists may be an alternative to increasing inhaled corticosteroids (Level III), but are not recommended as replacement therapy for inhaled corticosteroids.

Newer therapies such as long-acting β₂-agonists and leukotriene-receptor antagonists have been shown to be effective second line therapy in the management of asthma (Level II). Leukotriene-receptor antagonists may be an alternative to increasing inhaled corticosteroids (Level III), but are not recommended as first line anti-inflammatory therapy in place of inhaled corticosteroids. They may, however, be used when a person with asthma cannot or will not use inhaled corticosteroids (Level IV).

Nurses need to be knowledgeable about the various medications within each category (Level IV). Knowledge of medications includes the following:

- trade and generic names;
- indications;
- doses;
- side effects;
- mode of administration; and
- pharmacokinetics.
Medications: Relievers & Controllers

The following table provides a comparison of asthma medications (relievers and controllers), their actions, side effects and pharmacokinetics.

MDI(CFC) – Metered dose inhaler, chlorofluorocarbon propelled
MDI(HFA) – Metered dose inhaler, hydrofluoroalkane propelled
PD – Powder Device

Relievers

<table>
<thead>
<tr>
<th>Medications</th>
<th>Actions</th>
<th>Side Effects</th>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short acting β2 agonists:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>salbutamol</td>
<td>• Promotes bronchodilation through stimulation of β2-adrenergic receptors thereby relaxing airway smooth muscle</td>
<td>• tremor</td>
<td>salbutamol</td>
</tr>
<tr>
<td>• Airomir® MDI (HFA) 100µg</td>
<td><strong>Onset of action:</strong> a few minutes</td>
<td>• tachycardia</td>
<td>Absorption: 20% inhaled, well absorbed (PO)</td>
</tr>
<tr>
<td>• Apo-Salvent® MDI(CFC) 100µg</td>
<td><strong>Peaks:</strong> 15-20 minutes</td>
<td>• headache</td>
<td>Distribution: 30% inhaled, crosses blood–brain barrier, crosses placenta</td>
</tr>
<tr>
<td>• Novo-salmol® MDI(CFC) 100µg</td>
<td><strong>Duration:</strong> 2-4 hours, fenoterol up to 8 hours</td>
<td>• nervousness</td>
<td>Metabolism: liver extensively, tissues</td>
</tr>
<tr>
<td>• Ventolin® Diskus® PD 200µg</td>
<td></td>
<td>• palpitations</td>
<td>Excretion: mostly urine, feces, breast milk</td>
</tr>
<tr>
<td>• Ventolin® MDI(HFA) 100µg</td>
<td></td>
<td>• insomnia</td>
<td>Half-Life: 4-6 hrs</td>
</tr>
<tr>
<td>• Ventolin® Nebuamp® Wet Nebulization 1.25 or 2.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>terbutaline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Bricanyl® Turbuhaler® PD 500µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fenoterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Berotec® MDI 100µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Berotec® vials Wet Nebulization 0.25 mg/ml, 0.625 mg/ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ipratropium bromide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Atrovent® MDI 20µg,</td>
<td>• An anticholinergic drug that has been shown to have bronchodilator properties</td>
<td>• dry mouth</td>
<td>ipratropium bromide</td>
</tr>
<tr>
<td>• Atrovent® Wet Nebulization 125µg and 250 µg/ml</td>
<td>• Reduces vagal tone to the airways</td>
<td>• bad taste</td>
<td>Absorption: minimal</td>
</tr>
<tr>
<td></td>
<td><strong>Onset of action:</strong> 5-15 minutes</td>
<td>• tremor</td>
<td>Distribution: does not cross blood–brain barrier</td>
</tr>
<tr>
<td></td>
<td><strong>Peaks:</strong> 1-2 hours</td>
<td></td>
<td>Metabolism: liver, minimal</td>
</tr>
<tr>
<td></td>
<td><strong>Duration:</strong> 4-5 hours</td>
<td></td>
<td>Excretion: urine, feces</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Half-Life: 3-5 hrs</td>
</tr>
</tbody>
</table>
### Medications

<table>
<thead>
<tr>
<th><strong>Medications</strong></th>
<th><strong>Actions</strong></th>
<th><strong>Side Effects</strong></th>
<th><strong>Pharmacokinetics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methylxanthine:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aminophylline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Phyllocontin® SRT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>theophylline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Apo-Theo-LA SRT®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Quibron-T®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Theochron SRT®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Theolair SRT®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-Hour: theophylline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uniphyl®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glucocorticosteroids (inhaled):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>beclomethasone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Alti-beclomethasone MDI(CFC) 50µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• QVAR® MDI(HFA) 50µg, 100µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>budesonide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Pulmicort® Nebuamp® Wet Nebulization 0.125mg/ml, 0.25mg/ml and 0.5mg/ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Pulmicort® Turbuhaler® PD 100µg, 200µg and 400µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluticasone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Flovent® Diskus® PD 50µg, 100µg, 250µg and 500µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Flovent® MDI(CFC) 25µg, 50µg, 125µg and 250µg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Controllers

<table>
<thead>
<tr>
<th><strong>Medications</strong></th>
<th><strong>Actions</strong></th>
<th><strong>Side Effects</strong></th>
<th><strong>Pharmacokinetics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticosteroids (inhaled):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>beclomethasone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absorption: 20%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution: 10-25% in airways (no spacer)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism: minimal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excretion: less than 10% in urine/feces</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Half-Life: 15 hrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>budesonide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absorption: 39%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution: 10-25% in airways (no spacer)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism: liver</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excretion: 60% urine, smaller amounts in feces</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Half-Life: 2-3 hrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluticasone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absorption: 30% aerosol, 13.5% powder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution: 10-25% in airways (no spacer), 91% protein binding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism: liver</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excretion: less than 5% in urine, 97-100% in feces</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Half-Life: 14 hrs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Actions:**
- Prevents and suppresses activation and migration of inflammatory cells
- Reduces airway swelling, mucus production, and microvascular leakage
- Increases responsiveness of smooth muscle beta receptors

**Inhaled route:** (up to equivalent of 1000 µg/day beclomethasone):
- Sore throat
- Hoarse voice
- Thrush
- Rinsing, gargling and expectorating after inhalation can minimize these side effects.
- A spacer should be used with MDIs in order to assist in further reduction of possible side effects.

**Pharmacokinetics:**
- **beclomethasone**
  - Absorption: 20%
  - Distribution: 10-25% in airways (no spacer)
  - Metabolism: minimal
  - Excretion: less than 10% in urine/feces
  - Half-Life: 15 hrs
- **budesonide**
  - Absorption: 39%
  - Distribution: 10-25% in airways (no spacer)
  - Metabolism: liver
  - Excretion: 60% urine, smaller amounts in feces
  - Half-Life: 2-3 hrs
- **fluticasone**
  - Absorption: 30% aerosol, 13.5% powder
  - Distribution: 10-25% in airways (no spacer), 91% protein binding
  - Metabolism: liver
  - Excretion: less than 5% in urine, 97-100% in feces
  - Half-Life: 14 hrs
<table>
<thead>
<tr>
<th>Medications</th>
<th>Actions</th>
<th>Side Effects</th>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticosteroids (oral/intravenous):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ORAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>prednisone • Prednisone 5 mg and 50 mg tablets</td>
<td></td>
<td></td>
<td>prednisone • Absorption: well absorbed • Distribution: widely distributed; crosses placenta • Metabolism: liver, extensively • Excretion: urine, breast milk • Half-Life: 3-4 hrs</td>
</tr>
<tr>
<td>methylprednisolone • Medrol® 4 mg and 16 mg tablets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INTRAVENOUS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methylprednisolone • SoluCortef® • SoluMedrol®</td>
<td></td>
<td></td>
<td>IV steroids: • Absorption: rapid • Distribution: widely distributed • Metabolism: liver • Excretion: urine • Half-Life: 18 to 36 hrs, depending on the drug</td>
</tr>
<tr>
<td><strong>Long-Acting β₂ agonists:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>formoterol • Foradil® PD 12µg • Oxeze® Turbuhaler® PD 6µg and 12µg</td>
<td>• Promotes bronchodilation through stimulation of β₂-adrenergic receptors thereby relaxing airway smooth muscle</td>
<td>• tremor • tachycardia • headache • nervousness • palpitations • insomnia</td>
<td>formoterol • Absorption: rapid, lung deposition 21-37% • Distribution: plasma protein binding approximately 50% • Metabolism: liver, extensive • Excretion: 10% unchanged in urine • Half-Life: approximately 8-10 hours</td>
</tr>
<tr>
<td>salmeterol • Serevent® Diskus® PD 50µg • Serevent® MDI(CFC) 25µg</td>
<td>• Onset of action: 10-20 minutes • Duration: 12 hours</td>
<td></td>
<td>salmeterol • Absorption: minimal systemic • Distribution: local • Metabolism: liver first pass • Excretion: unknown • Half-Life: 5.5 hrs</td>
</tr>
<tr>
<td><strong>Salmeterol</strong></td>
<td>• Onset of action: 1-3 minutes • Duration: 12 hours</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma

## Nursing Best Practice Guideline

<table>
<thead>
<tr>
<th>Medications</th>
<th>Actions</th>
<th>Side Effects</th>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-Leukotrienes:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| *montelukast*  
• Singulair® 4 mg, 5mg and 10mg tablets | • Blocks the action of leukotrienes that are released by the membranes of inflammatory cells in the airways  
• *Note:* Bioavailability is reduced with zafirlukast (Accolate) when given with foods | *montelukast*  
• headache  
• abdominal pain  
• stomach upset  
• taken in the pm to help minimize side effects | *montelukast*  
Absorption: rapidly  
Distribution: protein binding 99%  
Metabolism: liver  
Excretion: bile  
Half-Life: 2.7-5.5 hrs |
| *zafirlukast*  
• Accolate® 20mg tablets | *zafirlukast*  
• headache  
• indigestion  
• stomach upset | | *zafirlukast*  
Absorption: rapid after oral administration  
Distribution: enters breast milk, 99% protein binding  
Metabolism: liver  
Excretion: feces, breast milk, 10% unchanged by kidneys  
Half-Life: 10 hrs |
| **Non-steroidal (anti-allergic) Anti-inflammatory:** | | | |
| *nedocromil sodium*  
• Tilade® MDI(CFC) 2mg | • Inhibits inflammatory cell mediators release from mast cells | *nedocromil sodium*  
• headache  
• stomach upset  
• bad taste  
• cough | *nedocromil sodium*  
Absorption: 90% inhaled dose swallowed; 2.5% of dose swallowed is absorbed; inhaled drug that reaches the lung is completely absorbed; bioavailability 6-9%  
Distribution: 28%-31% protein binding  
Metabolism: liver (metabolite)  
Excretion: unchanged in bile and urine  
Half-Life: 1.5-2.3 hrs |
| *sodium cromoglycate*  
• Intal Ampules® Wet Nebulization 2ml:10mg/ml  
• Intal® MDI(CFC) 1mg | *sodium cromoglycate*  
• throat irritation  
• cough | | *sodium cromoglycate*  
Absorption: poorly  
Distribution: unknown  
Metabolism: unknown  
Excretion: unchanged mostly in feces, bile and urine  
Half-Life: 80 min |
### Combination Drugs:

**Two bronchodilators:**
- ipratropium bromide and salbutamol
  - Combivent® MDI 20µg ipratropium/120µg salbutamol
  - Combivent® Wet Nebulization 0.5mg ipratropium/3mg salbutamol per 2.5ml vial

**Long-acting bronchodilators and inhaled steroids**
- fluticasone and salmeterol
  - Advair® Diskus® PD 100/50µg, 250/50µg, 500/50µg
  - Advair® MDI (HFA) 125/25µg, 250/25µg
- budesonide and formoterol
  - Symbicort® Turbuhaler® PD 100/6µg, 200/6µg

### Actions

- the same as those listed for each medication separately

### Side Effects

- 

### Pharmacokinetics

- 

---
Appendix E: Device Technique

Medications: Inhalation Devices
Adapted with permission from The Lung Association: www.lung.ca/asthma/manage/devices.html

Asthma medications come in many forms. However, most often they are taken by the inhaled route:
- Metered Dose Inhaler (puffer)
- Dry Powder Inhalers (Diskhaler®, Turbuhaler®, Diskus®)
- Nebulizer (used mostly with small children, therefore, not described in this Appendix)

Accurate technique for using these devices is extremely important. Individuals with asthma should review the accurate use of these devices with a nurse, pharmacist, Certified Asthma Educator or other appropriately trained health professional.

Inhalation Delivery System
The inhaled route is the most effective method to deliver the medication directly to the airways. As a result of using the inhaled route, the total dose of medication required is greatly reduced thereby reducing the chance for the medication to have a systemic effect.

A. Metered Dose Inhalers (MDI)
Metered dose inhalers (MDI), or puffers, deliver a precise dose of medication to the airways when used appropriately. It is very important to have a good technique. A holding chamber or spacer is recommended for use with a MDI, particularly for those not able to use a puffer accurately. To tell if the puffer is empty: (1) calculate the number of doses used, or (2) invert or shake it close to the ear several times and listen/feel for movement of liquid. One advantage of using the MDI is that it is quite portable. A number of different metered dose inhalers are available. Different pharmaceutical companies manufacture similar medications that are in different inhalers.
**Metered Dose Inhaler: Proper Use**

1. Remove the cap from the mouthpiece and shake the inhaler.
2. Breathe out to the end of a normal breath.
3. a) Position the mouthpiece end of the inhaler about 2-3 finger widths from the mouth, open mouth widely and tilt head back slightly, OR
   b) Close lips around the mouthpiece and tilt head back slightly.
4. Start to breathe in slowly, and then depress the container once.
5. Continue breathing in slowly until the lungs are full.
6. After breathing in fully, HOLD breath for 10 seconds or as long as possible, up to 10 seconds.
7. If a second puff is required, wait one minute and repeat the steps.

**Care of a Metered Dose Inhaler**

Keep the inhaler clean. Once a week, remove the medication canister from the plastic casing and wash the plastic casing in warm, soapy water. When the casing is dry, replace the medication canister in the casing and place the cap on the mouthpiece. Ensure that the hole is clear. Check the expiry date. Check to see how much medication is in the inhaler as described in the previous section.
Holding Chambers/Spacers
A number of different holding chambers are available from various companies. Different companies make different devices. All these devices are effective. The difference between them is the cost and durability.

Holding Chamber/Spacer
Holding chambers are devices that hold the medication for a few seconds after it has been released from the inhaler. This is helpful for people who have trouble coordinating the spray of the inhaler and breathing. It also allows the client the advantage of taking more than one breath in for each puff when unable to hold their breath, particularly in an acute episode or in the case of young children. There are masks available for adults or children with some of the devices. The client must remember to wait a minute between each puff of the inhaler, even when using a holding chamber. This ensures the client is receiving the prescribed amount of medication. Holding chambers are indicated for all individuals who:

- Use a Metered Dose Inhaler
- Have trouble coordinating the hand-breath step

When a holding chamber and inhaler are used, the larger particles drop down into the holding chamber. This limits the amount of particles in the mouth and throat, which in turn limits the amount absorbed systemically and reduces the chance of side effects.

Using a holding chamber may prevent the hoarse voice or sore throat which can occur with inhaled steroid use. Whether a holding chamber is used or not, individuals using inhaled steroids should gargle after treatment.
Holding Chamber: Proper Use
1. Remove the cap on the inhaler (MDI) and holding chamber mouthpiece.
2. Shake the inhaler well immediately before each use. Insert the inhaler (MDI) into the large opening of the inhaler adaptor on the chamber.
3. Put mouthpiece into mouth.
4. Depress inhaler (MDI) at beginning of slow deep inhalation. Hold breath as long as possible, up to 10 seconds before breathing out. If this is difficult, an alternative technique is to keep mouth tight on mouthpiece and breathe slowly 2-3 times after depressing inhaler (MDI).
5. Administer one puff at a time.
6. Slow down inhalation if you hear a “whistling” sound.
7. Follow instructions supplied with the inhaler (MDI) on amount of time to wait before repeating steps 3-6, as prescribed.
8. Remove the inhaler and replace the protective caps after use.

Care of a Holding Chamber
Whichever holding chamber is used, it must be cleaned at least once a week with warm soapy water, rinsed with clean water, and air dried in a vertical position.

B. Dry Powder Inhalers (DPIs)
There are several dry powder inhalers available. Examples include the Diskhaler®, Turbuhaler® and the Diskus®.

General points of dry powder inhalers include:
- A quick forceful inspiration is required to deliver the medications to the lungs, versus a slow breath for MDIs.
- Some Dry Powder Inhalers contain a lactose carrier or filler.
Diskhaler®: Proper Use of a Diskhaler®
1. To load the Diskhaler®, remove the cover & cartridge unit.
2. Place a disk on the wheel with the numbers facing up & slide the unit back into the Diskhaler®.
3. Gently push the cartridge in & out until the number 8 appears in the window.
4. The Diskhaler® is now ready for use.
5. Raise the lid up as far as it will go – this will pierce the blister.
6. Close the lid.
7. Breathe out.
8. Place the mouthpiece between the teeth and lips – make sure not to cover the air holes at the sides of the mouthpiece.
11. Hold breath for 10 seconds or as long as possible.
12. Sometimes 2 or 3 forceful breaths in are needed to make sure all the medication is taken.
13. If a second blister is prescribed, advance the cartridge to the next number and repeat steps 5-11.

Care of a Diskhaler®
Remove the cartridge and wheel. Clean any remaining powder away using the brush provided in the rear compartment before replacing the cartridge and wheel.

Turbuhaler®: Proper Use of a Turbuhaler®
1. Unscrew the cover and remove it.
2. Holding the device upright, turn the coloured wheel one way (right) and back (left) the other way until it clicks. Once the click is heard, the device is loaded.
3. Breathe out.
4. Place the mouthpiece between lips and tilt head back slightly.
5. Breathe in deeply and forcefully.
6. Hold breath for 10 seconds or as long as possible up to 10 seconds.
7. If a second dose is prescribed, repeat the steps.
When a red mark first appears in the little window, only twenty doses remain. The Turbuhaler® is empty and should be discarded when a red mark reaches the lower edge of the window. Newer Turbuhaler® devices have a counter that appears in a little window to show the number of doses left.

**Care of a Turbuhaler®**

Clean the mouthpiece two or three times a week. Using a dry cloth, wipe away any particles which have collected on the mouthpiece. Never wash the mouthpiece.

**Diskus®: Proper Use of a Diskus®**

1. **Open** – Place thumb on thumb grip. Push thumb away from body as far as it will go.
2. **Slide** – Slide the lever until a click is heard. Breathe out away from the Diskus®.
3. **Inhale** – Seal lips around the mouthpiece. Breathe in steadily and deeply through mouth. Hold breath for about 10 seconds, and then breathe out slowly.
4. **Close** – Place thumb on thumb grip, and slide the thumb grip towards body, as far as it will go.

Important: If more than one dose is prescribed, repeat steps 2-4. Rinse your mouth after using Flovent® or Advair®.

**Care of a Diskus®**

The dose counter displays how many doses are left or when the inhaler is empty. Keep the Diskus® closed when not in use, and only slide the lever when ready to take a dose.
Appendix F: What is an Asthma Action Plan?

What is an Asthma Action Plan?
An asthma action plan is an individualized written plan developed for the purpose of client self-management of asthma (Gibson et al., 1999). The plan guides self-monitoring of asthma based on symptoms, reliever use and perhaps peak flow measurements, and details the management steps to take according to the level of asthma control. The action plan is tailored to the individual’s preferences, treatment and usual pattern of exacerbations, and may incorporate triggers. Action plans should be developed in partnership with clients.

Often asthma action plans use a traffic light analogy having a green, a yellow, and a red zone. The green zone represents a time of acceptable and stable asthma control, and a “go ahead” with current therapy. The yellow zone represents a time of “caution” in that there are signs of worsening asthma and asthma control being lost. In response to this loss of control, suggestions may be made to adjust medications and/or seek medical assistance. The red zone represents a time of “danger” where asthma is identified as being out of control and severe enough to warrant urgent medical attention.

When should a written Asthma Action Plan be provided?
The Canadian Asthma Consensus Report (1999) recommends that every individual with asthma have a written action plan. An Ontario based survey of physicians observed that less than 25% of physicians provided written action plans. Those with more severe asthma were more likely than those with less severe asthma to receive an action plan (Cicutto et al., 1999).

An initial action plan should be provided when the diagnosis of asthma is established and/or at the time of discharge from the emergency department or hospital. The level of detail in the plan is dependent on the individual’s understanding and preferences. Key components for teaching a patient how to use an action plan includes the signs and symptoms of worsening asthma, how to adjust medications and when to seek medical attention, either an office visit or urgent care. If the client has an action plan, careful questioning about the most recent episode will elicit understanding of the plan, assess skills needed for executing the plan, and identify the need for further education.
Key Points
- The core of asthma management is the individualized asthma action plan.
- An action plan outlines the criteria for determining control and informs the client of the necessary steps to maintain or regain asthma control.
- Overall, an action plan provides clients with a framework to understand their asthma management.

What Should the Nurse Do?

Ask client if she/he has a written action plan.

YES
- Assess client’s knowledge and use of action plan
- Assess inhaler technique

NO
- Discuss role and rationale of action plan
- Provide sample plan to complete with physician (Appendix G)
- Assess inhaler technique
**Appendix G: Sample Action Plans**

<table>
<thead>
<tr>
<th>Sample 1: Firestone Institute for Respiratory Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample 2: Kaiser Permanente Center for Health Research</td>
</tr>
<tr>
<td>Sample 3: Kingston General Hospital Action Plan</td>
</tr>
<tr>
<td>Sample 4: University Health Network – The Asthma &amp; Airway Centre, Toronto Western Hospital</td>
</tr>
</tbody>
</table>
It is important to tell every physician that you have asthma and the last date that you took prednisone.
If your pharmacist substitutes an inhaler with an unfamiliar name, please have them adjust this card.

**RESPIROLOGIST**

Name: __________________________
Phone: __________________________

**CLINIC NURSE**

Name: __________________________
Phone: __________________________

This card was brought up to date:
on ________ by __________________________
Please take this card to every doctor’s appointment.

**REGULAR TREATMENT**

<table>
<thead>
<tr>
<th>INHALERS</th>
<th>Number of</th>
<th>Times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advair</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>QVAR</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>Flovent</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>Pulmicort</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>Atrovent, Combivent</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>Oxeze</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>Serevent</td>
<td>( )</td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TABLETS**

<table>
<thead>
<tr>
<th>Number of</th>
<th>Times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablets</td>
<td></td>
</tr>
</tbody>
</table>

**RESCUE INHALER**

Use as needed for wheeze, shortness of breath, chest tightness or cough:
Airomir, Bricanyl, Salbutamol, Ventolin, Ozeze
Other: __________________________

**WHAT TO DO IF YOU BECOME WORSE**

If ANY of the following occur:
1. Increasing need for “rescue inhaler”.
2. Increase in cough and/or sputum.
3. Increase in symptoms on waking.
4. Awakened at night by symptoms.
5. Peak flow rate after “rescue inhaler” is below ________

**YOU MUST INCREASE TREATMENT TO:**

<table>
<thead>
<tr>
<th>Number of</th>
<th>Times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalers</td>
<td></td>
</tr>
<tr>
<td>QVAR</td>
<td></td>
</tr>
<tr>
<td>Flovent</td>
<td></td>
</tr>
<tr>
<td>Pulmicort</td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
</tr>
</tbody>
</table>

**IF YOU CONTINUE TO GET WORSE AFTER INCREASING TREATMENT**

OR if your peak flow rate is below ________

**TAKE PREDNISONE TABLETS ( )**

Day 1 _________  Day 2 _________  Day 3 _________  Day 4 _________  Day 5 _________  Day 6 _________  Day 7 _________  Day 8 _________  Day 9 _________  Day 10 _________

**WHEN TO CONTACT YOUR DOCTOR**

• If you continue to get worse OR
• If symptoms and/or peak flow rates are not back to your best in 5 days.

Please note: This action plan is designed as a three-fold pamphlet.

**ASHTMA TREATMENT CARD**

**FIRESTONE INSTITUTE FOR RESPIRATORY HEALTH**

St. Joseph’s Healthcare
Hamilton, Ontario, L8N 4A6

Patient Name: __________________________

Patient: __________________________

This card was brought up to date:
on ________ by __________________________
Please take this card to every doctor’s appointment.

Sample 1: Firestone Institute for Respiratory Care
Reproduced with permission of the Firestone Institute for Respiratory Care, St. Joseph's Healthcare, Hamilton, Ontario
Sample 2: Kaiser Permanente Center for Health Research (Symptom Monitoring)
Reproduced with permission of the Kaiser Permanente Center for Health Research, Portland, Oregon.

<table>
<thead>
<tr>
<th>LEVEL</th>
<th>STATUS</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Clear</td>
<td></td>
<td><strong>TAKE:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>________</td>
</tr>
<tr>
<td></td>
<td></td>
<td>________</td>
</tr>
<tr>
<td></td>
<td></td>
<td>________</td>
</tr>
<tr>
<td>Caution</td>
<td></td>
<td><strong>ADD:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>________</td>
</tr>
<tr>
<td>Medical Alert</td>
<td></td>
<td><strong>ADD:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>________</td>
</tr>
</tbody>
</table>

**LEVEL STATUS ACTION**

<table>
<thead>
<tr>
<th>Medicine Dose Max # Times/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>_______</td>
</tr>
<tr>
<td>_______</td>
</tr>
<tr>
<td>_______</td>
</tr>
</tbody>
</table>

**Return to Level 1 when symptoms improve.**

**DANGER SIGNS**

- Difficulty walking and talking due to shortness of breath
- Lips or fingernails are blue

**GO TO THE HOSPITAL NOW OR CALL 911 NOW**
Sample 2: Kaiser Permanente Center for Health Research (Peak Flow Monitoring)

Reproduced with permission of the Kaiser Permanente Center for Health Research, Portland, Oregon.

<table>
<thead>
<tr>
<th>LEVEL</th>
<th>STATUS</th>
<th>ACTION</th>
</tr>
</thead>
</table>
| **Green Zone: All Clear**<br>My best peak flow: ____________<br>Peak Flow _______ to _________<br>(100 to 80% of my best peak flow)<br>■ No symptoms of an asthma episode<br>■ Able to do usual activities<br>■ Usual medications control asthma | 1 | DOING WELL<br>TAKE:<br>Medicine Dose Max # Times/day<br>______________________
______________________
______________________ |
| **Yellow Zone: Caution**<br>Peak Flow _______ to _________<br>(80 to 50% of my best peak flow)<br>■ Increased asthma symptoms<br> (including wakening at night due to asthma)<br>■ Usual activities somewhat limited<br>■ Increased need for asthma medications | 2 | INCREASE IN SYMPTOMS<br>ADD:<br>Medicine Dose Max # Times/day<br>______________________ |
| **Red Zone: Medical Alert**<br>Peak Flow _______ Less than _________<br>(50% of my best peak flow)<br>■ Increased symptoms longer than 24 hrs<br>■ Very short of breath<br>■ Usual activities severely limited<br>■ Asthma medications haven’t reduced symptoms | 3 | NO IMPROVEMENT AFTER ___ HRS OR EVEN MORE SYMPTOMS<br>ADD:<br>Medicine Dose<br>______________________
| **DANGER SIGNS** |  | AND CALL YOUR PROVIDER |
| | | GO TO THE HOSPITAL NOW OR CALL 911 NOW |

GO TO THE HOSPITAL NOW OR CALL 911 NOW
Sample 3: Kingston General Hospital Asthma Action Plan
Reproduced with the permission of Kingston General Hospital, Kingston, Ontario.

“Asthma Action Plan”

For: ____________________________________________

Predicted Peak Flow: ____________  *Personal Best Peak Flow: ____________

Developed By: ___________________________  Date: ___________________________

Approved By: ___________________________  Date: ___________________________

*Your action plan will be based on this number.

(This Action Plan is not considered active until approved and signed by a physician)

Maintenance Medications:
Reliever: ____________________________

Controller: ____________________________

Other: ____________________________

Your Asthma Is In Control If:

- You have no symptoms at rest, play, during the night or upon awakening.
- You need your reliever medication less than four times per week (not including prior to exercise or exposure to triggers).
- Your breathing tests and/or peak flow readings are normal for you.

Caution:
If at any time you:
- Are unsure
- Feel panicky
- Feel an overwhelming sense of doom

Contact your physician or go to emergency immediately. This action plan is a guideline only.
<table>
<thead>
<tr>
<th>GREEN ZONE: In Control</th>
<th>YELLOW ZONE: Worsening Asthma</th>
<th>RED ZONE: Severe Asthma</th>
<th>EXTRA RED ZONE: Medical Emergency</th>
</tr>
</thead>
<tbody>
<tr>
<td>- You have no symptoms;</td>
<td>- You are short of breath on moderate activity, and/or</td>
<td>- Your reliever is lasting 2 hours or less and/or</td>
<td>- Your reliever is lasting 2 hours or less and/or</td>
</tr>
<tr>
<td>- You are able to do normal activities and/or sports without being short of breath;</td>
<td>- You need your reliever more often than usual, and/or</td>
<td>- You do not feel better or your PEFR is under ______ (70% personal best) 20 to 60 minutes after taking your reliever and/or</td>
<td>- You are unable to talk in sentences and/or</td>
</tr>
<tr>
<td>- You are not waking up at night or early in the morning due to your asthma;</td>
<td>- You are waking at night or early in the morning with asthma symptoms, and/or</td>
<td>- You are short of breath, wheezing and/or have trouble breathing at rest or with normal activities.</td>
<td>- You have blueness around your lips and nails and/or</td>
</tr>
<tr>
<td>- You are using your normal amount of reliever medication.</td>
<td>- You are getting a cold.</td>
<td>- OR</td>
<td>- You are frightened by your asthma and/or</td>
</tr>
<tr>
<td>OR</td>
<td>OR</td>
<td></td>
<td>- You are having a sudden severe attack.</td>
</tr>
<tr>
<td>Peak Flow Above: _______ (≥80% personal best)</td>
<td>Peak Flow between: _______ and _______ (60-80% personal best)</td>
<td>Peak Flow between: _______ and _______ (50-60% personal best)</td>
<td>Peak Flow below: _______ (&lt;50% personal best)</td>
</tr>
</tbody>
</table>

| | | | |
| - Take your _________ (controller) _______ puffs _______ times per day even if you are feeling well; | - Take your _________ (controller)_________ puffs _______ times per day for 10-14 days and then return to the “Green Zone”; | - Take your _________ (reliever) _______ puffs every 20 minutes up to a total of 3 times and then every 4 hours; | - Go directly to Emergency or |
| - Take your other maintenance medication as prescribed; | - Take your _________ (reliever)_______ puffs every 4 hours as necessary to relieve symptoms; | - Take prednisone ______ mg now and daily for the next ______ days; | - Dial 911; |
| - Take your _________ (reliever) _______ puffs prior to exercise or exposure to triggers if necessary or for occasional symptoms (shortness of breath, wheeze, cough). | - If no improvement in your symptoms and/or peak flows in 2 days or your reliever only lasts for 2-3 hours go to the “Red Zone”. | - Call your doctor and see him/her within 24 hours or right away if getting worse. | - Take your reliever medication as necessary on the way to the hospital. |

■ Take your ___________ (controller) ___________ time(s) per day even if you are feeling well;
■ Take your other maintenance medication as prescribed;
■ Take your ___________ (reliever) ___________ puffs prior to exercise or exposure to triggers if necessary or for occasional symptoms (shortness of breath, wheeze, cough).
Sample 4: Toronto Western Hospital of the University Health Network

Reproduced with the permission of the Asthma and Airway Centre
University Health Network – Toronto Western Hospital, Toronto, Ontario

Management Plan based on Peak Flows:

*It is important to know what to do in case you have a severe asthma attack / episode.

Using your peak flows as a guide after establishing your personal best:

<table>
<thead>
<tr>
<th>Predicted peak flow</th>
<th>..........</th>
<th>L/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best peak flow</td>
<td>..........</td>
<td>L/min 80 – 100%</td>
</tr>
<tr>
<td>Peak flow requiring additional medications</td>
<td>..........</td>
<td>L/min 60 – 80%</td>
</tr>
<tr>
<td>Peak flow requiring urgent medical attention</td>
<td>..........</td>
<td>L/min Less than 60%</td>
</tr>
</tbody>
</table>

N.B. Your Peak flows should be reviewed by your healthcare provider intermittently.

Signs of Poor Asthma Control:

- Having cough, wheeze, chest tightness or shortness of breath during the day or night
- Need your quick relief inhaler more than 4 times a week (one dose before exercise)
- Unable to tolerate usual activities
- Lower peak flows than usual

If you are having any of the above symptoms – follow the instructions indicated in your Action Plan on the other side of this card or see your doctor.

**EMERGENCY ACTION PLAN WHEN...**

- You are not getting relief from your reliever (blue) inhaler
- You have trouble breathing and talk
- Your nails and lips are blue/grey
- You are feeling very tired, or having fear of dying - DO NOT DELAY GET HELP IMMEDIATELY CALL 911

You can take 2 – 3 puffs of your quick relief inhaler every 10 – 15 minutes on your way to the hospital, preferably by ambulance.

Regular Maintenance Medication

<table>
<thead>
<tr>
<th>Regular Medication</th>
<th>Drug Action</th>
<th>Dose</th>
<th>Times</th>
<th>Instructions</th>
<th>Common Side effects</th>
</tr>
</thead>
</table>

Action Plan if your asthma worsens:

Step 1. Use your quick reliever ................. ....... puffs every ....... hours if necessary.

Step 2. Start / Increase ................. ....... puffs ...... times a day until well or (Peak Flows back to usual best ............)
then decrease ................. ................. to your usual maintenance dose.

Step 3. If not getting better or (Peak Flows less than ...........) start Prednisone ....... mg for ...... days. See your Doctor .................

Step 4. For severe episodes seek Emergency help – see Emergency Action Plan on other side of this card.

Keep Your Asthma Under Control

- Always keep your quick relief inhaler with you while exercising
- Always keep your quick relief inhaler with you while exercising
- Keep follow-up appointments
- Carry this card with you at all times
- Consider your asthma when making travel plans

Developed by Kay Khan RN, CAE, Clinical Nurse Educator
www.AsthmaCentre.com

Emergency Department
Toronto Western Hospital
416 – 803 – 5717

RANAO
### Appendix H: Peak Flow Monitoring Tips

1. Monitoring Peak Expiratory Flow (PEF) may be useful in some clients, particularly those who are poor perceivers of airflow obstruction.

2. Caution should be exercised in interpreting PEF results, as they are extremely effort dependent, and should be used in conjunction with other clinical findings.

3. The client’s PEF technique should be observed until the practitioner is satisfied that the technique produces accurate readings. (See Appendix I)

4. Home PEF should be linked to the assessment of symptoms in the action plan.

5. Clients who are using a PEF meter should be instructed on how to establish their personal best PEF and use it as the basis of their action plan.

6. PEF devices must be checked regularly for accuracy and reproducibility of results.

7. Baseline morning and evening monitoring should be carried out over a number of weeks and continued regularly, with the frequency adjusted to the severity of the disease.

8. Clients should be alerted to the significance of increased diurnal variation (evening to morning changes) in PEF greater than 15-20%.

9. The accuracy of a client’s peak flow meter should be determined at least once a year or any time there is a question about its accuracy. Values from spirometry or another portable meter should be compared.

### Samples of Peak Flow Meters

- **Mini Wright® Peak Flow Meter**
- **Vitalograph® asmaPLAN+**
- **Truzone® Peak Flow Meter**
Appendix I: How to use a Peak Flow Meter (PFM)

Follow these five steps for using a Peak Flow Meter:

1. Move the indicator to the bottom of the numbered scale.
2. Stand up, or sit upright.
3. Take a deep breath in, and fill lungs completely.
4. Place the mouthpiece in mouth and close lips around it.
5. Blow out as hard and fast as possible in a single blow.

- Write down the value. If coughing occurred, the value is inaccurate. Do not record.
- Repeat the test.
- Repeat steps 1 through 5 two more times.
- Take the highest result of the three, and record.

Finding the Personal Best Peak Flow Number

The client’s personal best peak flow number is the highest peak flow number achieved over a 2 to 3 week period when asthma is under good control.

Each client’s asthma is different, and the “best” peak flow value may be higher or lower than another person’s of the same height, weight, and sex. The action plan needs to be based on the client’s personal best peak flow value.

To identify the client’s personal best peak flow number, have the client take peak flow readings:
- At least twice a day for 2 to 3 weeks.
- Upon awakening and before bed.
- Prior to and 15 minutes after taking a short-acting inhaled bronchodilator (reliever).
Appendix J: Tips for Improving Adherence

- Build a partnership with the client by establishing mutual goals for asthma care.
- Assess individual barriers to adherence, including misperceptions regarding asthma and its management.
- Assess any cultural or ethnic beliefs or practices that may influence self-management activities, i.e., “In your community, what does asthma mean?”
- Display open communication by showing attentiveness (i.e., eye contact), providing encouragement with non-verbal communication (i.e., smiling, nodding), using verbal praise for effective management strategies (i.e., “That is great” or “You did the right thing”), and using interactive conversation style (i.e., ask open-ended questions).
- Language should be clear, unambiguous, and presented using non-technical language. Make sure that you seek client feedback and elicit their understanding.
- Tailor the level and amount of education to suit the client.
- Provide client education using multiple teaching strategies (discussion, written materials, video, interactive websites).

Ensure that clients with asthma have adequate information to facilitate appropriate self-management.

- Promote the use of a written individualized asthma action plan.
- Simplify treatment and the action plan as much as possible.
- Encourage the client to use activities of daily living (i.e., shaving, brushing teeth, meal time) as reminders to take medication.
- Review and reinforce good inhaler technique.
- Education to improve medication adherence should address the following:
  - The severity of the client’s asthma.
  - The pros and cons to treatment options.
  - The consequences of not following the treatment plan.
  - Erroneous beliefs that asthma medications are not needed.
  - Issues related to asthma medications:
    - Side effects of medications.
    - Clarify misperceptions, particularly related to use of steroids.
Appendix K: Resources

Resources for Assisting with Client Asthma Education:
Practice settings may access resources for educational materials and tools to provide asthma education through several sources:

- The Asthma Society of Canada 1-800-787-3880
- The Lung Association 1-800-972-2636
- Asthma and Allergy Information Association
- Local community asthma clinics – see Appendix L
- Pharmaceutical Companies:
  - Contact your local pharmaceutical representative.
  - Teaching Tools: Inhaler placebos, spacers, peak flow meters, posters.

Recognized Healthcare Internet websites:
- The Asthma Centre – University Health Network – www.uhn.ca/programs/asthma/
- Asthma in Canada – www.asthmaincanada.com
- Asthma Society of Canada – www.asthma.ca/adults
- Canadian Asthma Consensus Guidelines Secretariat – www.asthmaguidelines.com
- Canadian Network for Asthma Care – www.cnac.net
- Family Physician Airways Group of Canada – www.asthmaactionplan.com
- The Lung Association – www.lung.ca

Opportunities for Continuing Professional Development in Asthma Care:
Canadian Network for Asthma Care (CNAC) Approved Asthma Educator Programs:
The Canadian Network for Asthma Care (CNAC) has approved several asthma educator programs. Please refer to their website (www.cnac.net) for a full listing of approved programs. The Michener Institute for Applied Health Sciences is the primary program in Ontario. Subject to other criteria for certification, graduates of these approved programs will be eligible to sit for the Certified Asthma Educator (C.A.E.) Examination.
Asthma Educator Program of The Michener Institute for Applied Health Sciences –
Toronto, Ontario
For registration information:
Division of Continuing Education
The Michener Institute for Applied Health Sciences
222 St. Patrick Street, Toronto, ON M5T 1V4
Tel: 416-596-3101 ext 3162
1-800-387-9066 ext 3308
Email: ce@michener.ca
www.michener.ca

The Canadian Network for Asthma Care lists several approved programs provided in other
provinces and internationally by distance on their website at www.cnac.net/english/
certprograms.html.

The Lung Association
The Lung Association's (Ontario) professional section, the Ontario Respiratory Care Society, has an asthma educator's interest group. This group offers an annual seminar, several evening sessions, a newsletter and other educational opportunities throughout the year. Please refer to the Ontario Respiratory Care Society's home page at www.on.lung.ca/orcs/mission.html or contact them at orcs@on.lung.ca.
Appendix L: Asthma Clinics in Ontario

The Canadian Network for Asthma Care (CNAC) is an association of associations. Its mission statement is "through its member organizations, CNAC is dedicated to the promotion of asthma care and education in Canada with the ultimate goal of reducing illness and death caused by this common disease".

It coordinates several activities of its member organizations in the asthma education area. The CNAC does not offer medical advice, nor does it refer members of the public to medical practitioners. However, the CNAC maintains a self-reporting listing of organizations, agencies, and hospitals providing asthma education programs to individuals affected with asthma for all provinces in Canada. This listing is by province, including Ontario.

Current information regarding these programs, location, referral process and service focus is posted on the CNAC website at www.cnac.net/english/clinics.html.
Appendix M: Description of the Toolkit

Best practice guidelines can only be successfully implemented if there are: adequate planning, resources, organizational and administrative support as well as appropriate facilitation. In this light, RNAO, through a panel of nurses, researchers and administrators has developed a Toolkit: Implementation of Clinical Practice Guidelines based on available evidence, theoretical perspectives and consensus. The Toolkit is recommended for guiding the implementation of any clinical practice guideline in a healthcare organization.

The “Toolkit” provides step-by-step directions to individuals and groups involved in planning, coordinating, and facilitating guideline implementation. Specifically, the Toolkit addresses the following key steps in implementing a guideline:
1. Identifying a well-developed, evidence-based clinical practice guideline.
2. Identification, assessment and engagement of stakeholders.
3. Assessment of environmental readiness for guideline implementation.
4. Identifying and planning evidence-based implementation strategies.
5. Planning and implementing an evaluation.
6. Identifying and securing required resources for implementation and evaluation.

Implementing practice guidelines that result in successful practice changes and positive clinical impact is a complex undertaking. The Toolkit is one key resource for managing this process.

The Toolkit is available through the Registered Nurses Association of Ontario. The document is available in a bound format for a nominal fee, and is also available free of charge from the RNAO website. For more information, an order form or to download the Toolkit, please visit the RNAO website at www.rnao.org/bestpractices.
Appendix N: Implementation Resources

The following “patient pathway” was developed by Trillium Health Care, the acute care community-based hospital that pilot implemented this best practice guideline. This pathway is included here as an example of how one practice setting adapted the recommendations in this guideline to meet their local needs. This tool allowed the nurses to target their assessment and teaching to meet the patient's needs, and to reduce duplication in care.

Reproduced with permission of Trillium Health Centre, Mississauga, Ontario.
Notes:
Notes:

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________
Notes:
Supplement Integration

This supplement to the nursing best practice guideline *Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma* is the result of a three year scheduled revision of the guideline. Additional material has been provided in an attempt to provide the reader with current evidence to support practice. Similar to the original guideline publication, this document needs to be reviewed and applied, based on the specific needs of the organization or practice setting/environment, as well as the needs and wishes of the client. This supplement should be used in conjunction with the guideline as a tool to assist in decision making for individualized client care, as well as ensuring that appropriate structures and supports are in place to provide the best possible care.

A review of the literature suggests that adult asthma continues to be poorly controlled and remains a primary goal for asthma care. A Canadian study, *The Reality of Asthma Control (TRAC)*, revealed that 97% of individuals thought their asthma was well controlled; however, only 47% had controlled disease (Fitzgerald et al., 2006). Action plans remain an essential component of asthma care but only 11% of individuals have an action plan. Since the publication of our original asthma guideline in 2004, there have not been dramatic changes in asthma care. A review of the most recent literature and asthma practice guidelines published in Canada, the United States, the United Kingdom and from the World Health Organization over the last 3-4 years does not suggest dramatic changes to our approach to asthma care, but rather suggests some refinements and stronger evidence for our approach.

Revision Process

The Registered Nurses’ Association of Ontario (RNAO) has made a commitment to ensure that this practice guideline is based on the best available evidence. In order to meet this commitment, a monitoring and revision process has been established for each guideline every 3 years. The revision panel members (experts from a variety of practice settings) are given a mandate to review the guideline focusing on the recommendations and the original scope of the guideline.
Members of the panel critically appraised four international guidelines, published since 2002, using the Appraisal of Guidelines for Research and Evaluation Instrument (AGREE, 2001). The guidelines were:


The AGREE review resulted in all four of these guidelines being used to inform the revision process of the RNAO guideline.

**Background Context**

The following content is to be added to the discussion of “What is Asthma” on page 25 of the guideline: “Regardless of the client's asthma severity, any loss of asthma control can potentially be life-threatening. It is important to emphasize asthma control when a nurse is conducting an assessment rather than asthma severity. Labeling clients by severity can be misleading. A client that has “mild” asthma or “severe” asthma can have potentially life threatening asthma. The best way to prevent an asthma death is to keep asthma under good control regardless of severity.”

The definition of asthma control is evolving both nationally and internationally. The revision of this guideline is consistent with the current parameters for asthma control endorsed by the Canadian Asthma Consensus Report (Boulet et al., 1999). However, the revision panel acknowledges that the definition used in this supplement will require re-assessment once the most recent update of the Canadian Asthma Consensus Report is released, to ensure there is consistent messaging related to this important aspect of asthma management. The most recent edition of the GINA guidelines (GINA, 2006) suggest that the cut off for some of the criteria for assessing asthma control may be changing.

The following reference is to be added to the discussion of “What Causes Asthma” on pg. 26 of the guideline under the section related to “Irritants – Tobacco smoke”: RNAO guideline Integrating Smoking Cessation into Daily Nursing Practice (2003).

The wording of the subheading on page 27 is to be changed to read, “c) Other factors that can trigger or make asthma more difficult to control”. This is to emphasize the importance of achieving asthma control, regardless of asthma severity.
**Summary of Evidence**
The following content reflects the evidence reviewed that either supports the original guideline recommendations, or provides evidence for revision. Through the review process, no recommendations were deleted. However, a number of recommendations were re-worded for clarity or to reflect new knowledge and three new recommendations have been added.

### Practice Recommendations

<table>
<thead>
<tr>
<th><strong>Recommendation 1</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All individuals identified as having asthma, or suspected of having asthma, will have their level of asthma control assessed by the nurse.</strong></td>
<td>✔️</td>
</tr>
</tbody>
</table>

**Additional Literature Supports**
Bousquet et al., 2005

<table>
<thead>
<tr>
<th><strong>Recommendation 1.1</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Every client should be screened to identify those most likely to be affected by asthma. As part of the basic respiratory assessment, nurses should ask every client two questions:</strong></td>
<td>✔️</td>
</tr>
<tr>
<td>- Have you ever been told by a physician or a health care provider that you have asthma?</td>
<td></td>
</tr>
<tr>
<td>- Have you ever used a puffer/inhaler or asthma medication for breathing problems?</td>
<td>(Level IV)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Recommendation 1.2</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For individuals identified as having asthma or suspected of having asthma, the level of asthma control should be assessed by the nurse. Nurses should be knowledgeable about the acceptable parameters of asthma control which are:</strong></td>
<td>✔️</td>
</tr>
<tr>
<td>- use of inhaled short-acting β₂ agonist &lt;4 times/week (unless for exercise);</td>
<td></td>
</tr>
<tr>
<td>- having daytime asthma symptoms &lt;4 times/week;</td>
<td></td>
</tr>
<tr>
<td>- experience night-time asthma symptoms &lt;1 time/week;</td>
<td></td>
</tr>
<tr>
<td>- normal physical activity levels;</td>
<td></td>
</tr>
<tr>
<td>- no absence from work or school; and</td>
<td></td>
</tr>
<tr>
<td>- infrequent and mild exacerbations.</td>
<td>(Level IV)</td>
</tr>
</tbody>
</table>

The table on page 31 of the guideline should be updated to include a reference to the updated Canadian Asthma Consensus Report (Becker et al., 2003).

**Additional Literature Supports**
Becker et al., 2003

<table>
<thead>
<tr>
<th><strong>Recommendation 1.3</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For individuals identified as potentially having uncontrolled asthma, the level of acuity needs to be assessed by the nurse and an appropriate medical referral provided, i.e., urgent care or follow-up appointment.</strong></td>
<td>✔️</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Recommendation 2.0</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asthma education, provided by the nurse, must be an essential component of care.</strong></td>
<td>✔️</td>
</tr>
</tbody>
</table>

**Additional Literature Supports**
Mager et al., 2005
Recommendation 2.1
The client’s asthma knowledge and skills should be assessed and where gaps are identified, asthma education should be provided. (Level I)

Additional Literature Supports
Paasche-Orlow et al., 2005

Recommendation 2.2
Education should include as a minimum, the following:
- basic facts about asthma;
- roles/rationale for medications;
- device technique(s);
- self-monitoring;
- action plans; and
- smoking cessation (if applicable). (Level IV)

Additional Literature Supports
Paasche-Orlow et al., 2005

Recommendation 3.0
Every client with asthma should have an individualized written asthma action plan for guided self-management. (Level I)

This new recommendation has been created from the original Recommendation 3.1 which has been divided into two separate recommendations. The purpose of this change is to emphasize the importance of all clients with asthma having a written asthma action plan.

Additional Literature Supports
BTS/SIGN, 2004; GINA, 2006

Recommendation 3.1
An action plan should be developed in partnership with the healthcare professional and be based on the evaluation of symptoms with or without peak flow measurement. (Level I)

The wording of this recommendation has been modified to emphasize the fact that the client and healthcare professional should work in partnership to develop the action plan. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.

Additional Literature Supports
GINA, 2006; National Institutes of Health, 2003; Osman et al., 2002; Powell & Gibson, 2006; Smith et al., 2005
<table>
<thead>
<tr>
<th>Recommendation 3.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>For every client with asthma, the nurse needs to assess his/her understanding of the asthma action plan. If a client does not have an action plan, the nurse needs to provide a sample action plan, explain its purpose and use, and coach the client to complete the plan with his/her asthma care provider.</td>
</tr>
</tbody>
</table>

(Level V)  

<table>
<thead>
<tr>
<th>Recommendation 3.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Where deemed appropriate, the nurse should assess, assist and educate clients in measuring peak expiratory flow rates. A standardized format should be used for teaching clients how to use peak flow measurements.</td>
</tr>
</tbody>
</table>

(Level IV)  

<table>
<thead>
<tr>
<th>Recommendation 4.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nurses will understand and discuss asthma medications with their clients.</td>
</tr>
</tbody>
</table>

The wording of this recommendation has been modified to emphasize the need for action related to client education and medication use. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.  

<table>
<thead>
<tr>
<th>Recommendation 4.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nurses will understand and discuss the two main categories of asthma medications (controllers and relievers) with their clients.</td>
</tr>
</tbody>
</table>

The wording of this recommendation has been modified to emphasize the need for nursing intervention related to client education and medication use. As a component of asthma knowledge related to medications, there is an emphasis on the need for the nurse to have knowledge of both categories of asthma medications and proper device technique in order to provide client education.  

Additional Literature Supports  
Finn et al., 2003  

<table>
<thead>
<tr>
<th>Recommendation 4.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clients with asthma will have their inhaler/device technique assessed by the nurse to ensure accurate use. Clients with sub-optimal technique will be coached in proper inhaler/device use.</td>
</tr>
</tbody>
</table>

(Level I)  

The wording of this recommendation has been modified to emphasize that clients will have their inhaler/device technique assessed. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.  

<table>
<thead>
<tr>
<th>Recommendation 5.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>The nurse will facilitate referrals for clients with asthma as appropriate.</td>
</tr>
</tbody>
</table>

The wording of this recommendation has been modified to emphasize that it is clients with asthma who should be referred to an asthma educator and/or additional asthma resources in their community. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.  

---
**Recommendation 5.1**
*Clients with poorly controlled asthma will be advised to see a physician.*

The wording of this recommendation has been modified to emphasize that clients with poorly controlled asthma *will be advised* to see a physician. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.

Additional Literature Supports
Baren et al., 2001

**Recommendation 5.2**
*Clients with asthma should be offered links to community resources.*

The wording of this recommendation has been modified to emphasize that it is clients *with asthma* who should be offered links to community resources. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.

See Appendix K – pg. 13 of this supplement for additions to the published listing of community resources related to smoking cessation.

**Recommendation 5.3**
*Clients with asthma should be referred to an asthma educator in their community, if appropriate and available.*

The wording of this recommendation has been modified to emphasize that it is clients *with asthma* who should be referred to an asthma educator. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.

Additional Literature Supports
Powell & Gibson, 2006

**Education Recommendations**

**Recommendation 6.0**
*Nurses working with clients with asthma must have the appropriate knowledge and skills to:*

- Identify the level of asthma control;
- Provide basic asthma education; and
- Conduct appropriate referrals to physician and community resources.

The wording of this recommendation has been modified to emphasize that it is when nurses are working with *clients with asthma* that they must have the appropriate knowledge and skills. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.
## Organization and Policy Recommendations

**Recommendation 7.0**  
Access to asthma education should be available within a community.  
*(Level V)*  
This consensus recommendation has been made by the panel in the context of the strong evidence that supports asthma education to achieve and maintain asthma control, and the literature that indicates there is a lack of community asthma education programs.

Additional Literature Supports  
Boulet et al., 1999; Cowie, Cicuttio & Boulet, 2001; Gibson et al., 2006

**Recommendation 8.0**  
It is essential that asthma educators obtain and maintain the certified asthma educator (CAE) designation.  
*(Level V)*  
This consensus recommendation has been made by the panel in support of the Canadian Asthma Consensus Report (Boulet et al., 1999), which suggests that educational programs for asthma educators that result in national certification may standardize the information provided to clients with asthma, and improve the quality of client education. The Canadian Network for Asthma Care (2006) has established a national certification for asthma educators in Canada, which addresses two key aspects of asthma educator education: up-to-date knowledge about asthma; and a better understanding on the part of educators about educational theory and process (Cicuttio et al., 2005). National learning objectives (core curriculum) have been developed to provide a common set of technical and teaching competencies for Canadian asthma educators. Proficiency in these competencies is required for national certification (Canadian Network for Asthma Care, 2006).

Additional Literature Supports  
Boulet et al., 1999; Cicuttio et al., 2005; Canadian Network for Asthma Care, 2006

**Recommendation 9.0**  
Organizations should have available placebos and spacer devices for teaching, sample templates of action plans, educational materials, and resources for client and nurse education and where indicated, peak flow monitoring equipment.  
*(Level IV)*

**Recommendation 10.0**  
Organizations must promote a collaborative practice model within an interdisciplinary team to enhance asthma care.  
*(Level IV)*

**Recommendation 11.0**  
Organizations need to ensure that a critical mass of health professionals are educated and supported to implement the asthma best practice guidelines in order to ensure sustainability.  
*(Level V)*

**Recommendation 12.0**  
Agencies and funders need to allocate appropriate resources to ensure adequate staffing and a positive healthy work environment in order to provide asthma care consistent with best practice.  
*(Level V)*

Wording of the recommendation has been modified to emphasize that appropriate resources and work environment are necessary to provide asthma care consistent with best practice. The change in the wording is for clarification only, and there has been no change in the intent of the recommendation.

Additional Literature Supports  
RNAO, 2007 (in press)
**Recommendation 13.0**

*Healthcare organizations will use key indicators, outcome measurements, and observational strategies that allow them to monitor:*

- The implementation of guidelines;
- The impact of the guidelines on optimizing client care; and
- Efficiencies, or cost effectiveness achieved.

*(Level IV)*

A commitment to monitoring the impact of implementing the *Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma* best practice guideline is a key step to determine whether or not practice guidelines improve client outcomes. One way to approach this monitoring activity is to describe each recommendation to be implemented in measurable terms, so that the health care team can be involved in the evaluation and quality monitoring process. Refer to pg. 61 of the guideline for some suggested monitoring indicators.

**Additional Literature Supports**

Edwards et al., 2005; Hysong, Best & Pugh, 2006

---

**Recommendation 14.0**

*Nursing best practice guidelines can be successfully implemented only when there are adequate planning, resources, organizational and administrative support, and appropriate facilitation. Organizations may develop a plan for implementation that includes:*

- An assessment of organizational readiness and barriers to education.
- Involvement of all members (whether in a direct or indirect supportive function) who will contribute to the implementation process.
- Dedication of a qualified individual to provide the support needed for the education and implementation process.
- Ongoing opportunities for discussion and education to reinforce the importance of best practices.
- Opportunities for reflection on personal and organizational experience in implementing guidelines.

In this regard, RNAO (through a panel of nurses, researchers and administrators) has developed the Toolkit: Implementation of Clinical Practice Guidelines based on available evidence, theoretical perspectives and consensus. The Toolkit is recommended for guiding the implementation of Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma.

*(Level IV)*

**Additional Literature Supports**

Dobbins, Davies, Danseco, Edwards & Virani, 2005

---
Implementation Strategies

The Registered Nurses' Association of Ontario and the guideline panel have compiled a list of implementation strategies to assist health care organizations or health care disciplines who are interested in implementing this guideline. A summary of these strategies follows:

- Have at least one dedicated person such as an advanced practice nurse or a clinical resource nurse who will provide support, clinical expertise and leadership. The individual should have good interpersonal, facilitation and project management skills.
- Conduct an organizational needs assessment related to the care of adults with asthma to identify current knowledge and further educational requirements.
- Create a vision to help direct the change effort and develop strategies for achieving and sustaining the vision.
- Establish a steering committee comprised of key stakeholders and interdisciplinary members committed to leading the change initiative. Identify short term and long-term goals.
- Identify and support designated best practice champions on each unit to promote and support implementation. Celebrate milestones and achievements, acknowledging work well done (Davies & Edwards, 2004).
- Provide organizational support such as having the structures in place to facilitate best practices in asthma care. For example, having an organizational philosophy that reflects the value of best practices through policies and procedures. Develop new assessment and documentation tools (Davies & Edwards, 2004).

Research Gaps and Implications

A number of researchers have looked at health literacy in relation to self-management and chronic illnesses including the health outcomes of individuals living with asthma (Dewalt et al., 2004). In this research some measure of reading level has generally been used as a proxy for literacy. The limited research that has been done in relation to health literacy and asthma self-care demonstrates that higher literacy skills are associated with better self-care management (Dewalt et al., 2004; Paasche-Orlow et al., 2005; Rudd et al., 2004; Sleath et al., 2006; Williams et al., 1998). As indicated, it is clear that the use of action plans in the self-management of asthma is associated with improved asthma control (Gibson et al., 2006) and significantly reduced sudden death (Abramson et al., 2001). Although care providers believe that there is a relationship between literacy and asthma self-control (Forbis & Ailigne, 2002), to date no research has been identified examining the relationship between health literacy, the use of action plans and the maintenance of asthma control.

Appendices

The review/revision process did not identify a need for additional appendices; however updates to the following appendices are noted.

Appendix B: Glossary of Terms

The glossary has been updated to remove the term:

Metered Dose Inhaler, Chlorofluorocarbon Propelled – MDI(CFC): This device is no longer available in Canada.

The glossary has been updated to add the term:

Bronchospasm: A contraction of smooth muscle in the walls of the bronchi and bronchioles, causing narrowing of the lumen (airway).
Appendix D: Asthma Medications

The following two new medications have been added to the medication table (pg 74) under Controllers:

<table>
<thead>
<tr>
<th>Medications</th>
<th>Actions</th>
<th>Side Effects</th>
<th>Pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti – Immunoglobulin E (IgE) Neutralizing Monoclonal Antibody (Anti – IgE):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omalizumab</td>
<td>• Binds to IgE preventing binding of IgE to the high affinity FceRI receptor, thereby reducing the amount of free IgE that is available to trigger the allergic cascade.</td>
<td>• Anaphylaxis</td>
<td>Absorption: Average absolute bioavailability of 62%.</td>
</tr>
<tr>
<td>• Xolair® Subcutaneous 150mg. – 375mg. S.C. Q2 – 4 weeks.</td>
<td>• This medication prevents free serum IgE from attaching to mast cells and prevents IgE mediated inflammatory changes.</td>
<td>• Malignancy</td>
<td>Distribution: Peak serum concentrations after an average of 7 – 8 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Immunogenicity</td>
<td>Metabolism: Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Injection site irritation</td>
<td>Excretion: Involved with IgG clearance via liver – bile and in breast milk.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Viral infections</td>
<td>Half-Life: 26 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Upper respiratory tract infections</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sinusitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Headache</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sore throat</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergic:</strong></td>
<td>• Once inhaled, it is converted in the lungs to its active metabolite, which is a potent glucocorticoid that binds to glucocorticoid receptors in the lung resulting in local pronounced anti-inflammatory activity.</td>
<td>• Paradoxical bronchospasm</td>
<td>Absorption: The systemic bioavailability for the active metabolite is &gt;50% by using the ciclesonide MDI.</td>
</tr>
<tr>
<td>Ciclesonide</td>
<td></td>
<td></td>
<td>Distribution: High protein binding, approximately 1% is available for systemic exposure.</td>
</tr>
<tr>
<td>• Alvesco® MDI HFA 100 and 200 µg</td>
<td></td>
<td></td>
<td>Metabolism: Hydrolysed to its pharmacologically active metabolite by esterase enzymes primarily in the lungs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Excretion: Liver – bile</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Half-Life: Approximately 6 hours.</td>
</tr>
</tbody>
</table>

The following medication, included in the original guideline, has been updated as follows:

Controllers:

p. 74 – **Glucocorticoids (inhaled)** – Fluticasone (Flovent) is now available in HFA in 50, 125 and 250 µg doses.

The following medications have been removed from the table:

Controllers:

p. 74 – **Glucocorticoids (inhaled)** – Fluticasone (Flovent) MDI(CFC) is no longer available in Canada

p. 75 – **Long Acting & Agonists** – Salmeterol (Serevent) MDI(CFC) is no longer available in Canada

p. 76 – **Non-Steroidal Anti-inflammatory** – Sodium cromoglycate (Intal) MDI(CFC) is no longer available in Canada
Appendix G: Sample Action Plans

Sample 1 from Firestone Institute for Respiratory Care St. Joseph's Healthcare, Hamilton Ontario (pg 87 of the guideline) is replaced with the updated version St. Joseph’s Healthcare Hamilton "Asthma Treatment Card" below. Reproduced with permission.

### RESPIROLOGIST

<table>
<thead>
<tr>
<th>Dr:</th>
<th>Phone:</th>
</tr>
</thead>
</table>

### CLINIC NURSE

<table>
<thead>
<tr>
<th>Name:</th>
<th>Phone:</th>
</tr>
</thead>
</table>

This card was brought up to date:  
on __________ by __________  
Please take this card to every doctor’s appointment.

### REGULAR TREATMENT

#### INHALERS

<table>
<thead>
<tr>
<th>Inhaler</th>
<th>Number of inhalations</th>
<th>Times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QVAR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flovent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmicort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrovent, Combivent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxeze</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serevent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spiriva</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symbicort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### TABLETS

<table>
<thead>
<tr>
<th>Number of Tablets</th>
<th>Times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### WHAT TO DO IF YOU BECOME WORSE

If ANY of the following occur:
1. Increasing need for “rescue inhaler”.
2. Increase in cough and/or sputum.
3. Increase in symptoms on waking.
4. Awakened at night by symptoms.
5. Peak flow rate after “rescue inhaler” is below ______________________

YOU MUST INCREASE TREATMENT TO:

<table>
<thead>
<tr>
<th>Inhaler</th>
<th>Number of inhalations</th>
<th>Times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>QVAR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flovent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmicort</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### IF YOU CONTINUE TO GET WORSE AFTER INCREASING TREATMENT

OR if your peak flow rate is below __________

#### TAKE PREDNISONE TABLETS ( )

<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 2</td>
<td>Day 7</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>Day 8</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 4</td>
<td>Day 9</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 5</td>
<td>Day 10</td>
</tr>
</tbody>
</table>

### WHEN TO CONTACT YOUR DOCTOR

- If you continue to get worse OR
- If symptoms and/or peak flow rates are not back to your best in 5 days.

- If your phlegm is yellow or green, add:

### ASHMA TREATMENT CARD

FIRESTONE INSTITUTE FOR RESPIRATORY HEALTH  
St. Joseph’s Healthcare  
Hamilton, Ontario

<table>
<thead>
<tr>
<th>Patient Name:</th>
</tr>
</thead>
</table>

Please note: This action plan is designed as a three-fold pamphlet.
**Sample 2** from Kaiser Permanente Center for Health Research (pg 88 of guideline) is current, with no revisions noted.

**Sample 3** from Kingston General Hospital (pg 90 of the guideline) has been updated to reflect that the “Action Plan is not considered “active” until approved and signed by a physician”. Please note that if you are using this action plan as an example to develop an organization specific Asthma Action Plan, you should provide space for a physicians’ signature.

**Sample 4** from Toronto Western Hospital at the University Health Network, Toronto, Ontario (pg 92 of the guideline) is replaced with the updated version below.

Reproduced with permission

---

**Management Plan based on Peak Flows**

It is important to know what to do in case you have a severe asthma attack / episode.

**Using your best peak flows as your personal best:**

<table>
<thead>
<tr>
<th>Predicted peak flow</th>
<th>L/m</th>
<th>Personal Best peak flow</th>
<th>L/m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak flow requiring</td>
<td>80 – 100%</td>
<td>Additional Medications</td>
<td>L/m</td>
</tr>
<tr>
<td>Peak flow requiring urgent Medical attention</td>
<td>Less than 60%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.B. Your Peak flows should be reviewed by your healthcare provider intermittently.

---

**Signs of Poor Asthma Control**

- Having cough, wheeze, chest tightness or shortness of breath during the day or night
- Need your quick relief inhaler more than 4 times a week (one dose before exercise)
- Unable to tolerate usual activities
- Lower peak flows than usual

If you are having any of the above symptoms - follow instructions indicated in your Action Plan or see your doctor.

**EMERGENCY ACTION PLAN WHEN...**

- You are not getting relief from your reliever (blue) inhaler
- You have trouble breathing and talk
- Your nails and lips are blue/grey
- You are feeling very tired, or having fear of dying

**DO NOT DELAY GET HELP IMMEDIATELY CALL 911**

You can take 2 – 3 puffs of your quick relief inhaler every 10 – 15 minutes on your way to the Hospital, preferably by ambulance.

---

**Regular Maintenance Medication**

<table>
<thead>
<tr>
<th>Regular Medication</th>
<th>Drug Action</th>
<th>Dose</th>
<th>Times</th>
<th>Instructions</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Asthma Action Plan - see Signs for Poor Asthma Control**

**Step 1.** Use your quick reliever ............... puffs every ........... hours if necessary.

**Step 2.** Start / Increase ............... puffs ........... times a day for ........... days or (Peak Flows back to usual best ...........)
then decrease ............... to your usual maintenance dose.

**Step 3.** If not getting better or (Peak Flows less than ........... Start Prednisone ........... mg for ........... days. See your Doctor ............... steps.

**Step 4.** For severe episodes seek Emergency help – see Emergency Action Plan

---

**Keep Your Asthma Under Control**

- Practice preventive measures for asthma triggers
- Always keep your quick relief inhaler with you
- Take medications as prescribed
- Don’t ignore early warning signs of worsening asthma
- Know the actions and side effects of your medications
- Keep follow-up appointments
- Carry this card with you at all times
- Consider your asthma when making travel plans

---
Appendix H: Peak Flow Monitoring Tips

The labels of peak flow meters incorrectly identified on pg 93 of the guideline are corrected below. The samples illustrated here are the meters that are most commonly used.

Appendix K: Resources

The Educational Resources were reviewed in Appendix K for current contact information. The following updates to contact information for Appendix K are listed below:

- The Asthma Society of Canada: toll free number has been changed to: 1-866-787-4050 Toll Free  Website: www.asthma.ca/adults
- The Lung Association (Ontario Office): Number remains the same 1-800-972-2636
- The Asthma and Airway Centre – University Health Network: www.uhn.ca/Clinics & Services/clinics/asthma_airway.asp
- Family Physician Airways Group of Canada: Website: www.fpagc.com

The following resources have been added to this appendix to reflect the new focus on smoking cessation in asthma education provided to clients:

Resources for smoking cessation:

National
Canadian Cancer Society: www.cancer.ca
Smoker's Helpline: 1-877-513-5333
Smoker's Helpline Online: www.smokershelpline.ca
Canadian Council on Tobacco Control: www.cctc.ca
Health Canada: www.gosmokefree.ca
Heart and Stroke Foundation of Canada: www.heartandstroke.ca
Physicians for a Smoke Free Canada: www.smoke-free.ca

Provincial (Ontario)
Program Training and Consultation Centre: www.ptcc-cfc.on.ca
References


Bousquet, J. et al. (2005). The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy, 60(3), 302-308.


Finn, A. et al. (2003). Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. Journal of Allergy & Clinical Immunology, 111(2), 278-284.


Marabini, A. et al. (2002). Short-term effectiveness of an asthma educational program: Results of a randomized controlled trial. Respiratory Medicine, 96(12), 993-998.


